ALMA MATER STUDIORUM UNIVERSITȦ DI BOLOGNA

## ARCHIVIO ISTITUZIONALE DELLA RICERCA

## Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

A systematic review and meta-analysis of the association between young adults' sleep habits and substance use, with a focus on self-medication behaviours

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:
Meneo, D., Bacaro, V., Curati, S., Russo, P.M., Martoni, M., Gelfo, F., et al. (2023). A systematic review and meta-analysis of the association between young adults' sleep habits and substance use, with a focus on self-medication behaviours. SLEEP MEDICINE REVIEWS, 70, 1-20 [10.1016/j.smrv.2023.101792].

Availability:
This version is available at: https://hdl.handle.net/11585/961646 since: 2024-02-29
Published:
DOI: http://doi.org/10.1016/j.smrv.2023.101792

Terms of use:
Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/).
When citing, please refer to the published version.

A systematic review and meta-analysis of the association between young adults' sleep habits and substance use, with a focus on self-medication behaviours

Meneo $\mathrm{D}^{1}$, Bacaro $\mathrm{V}^{1,2}$, Curati $\mathrm{S}^{1}$, Russo $\mathrm{PM}^{3}$, Martoni $\mathrm{M}^{3}$, Gelfo $\mathrm{F}^{1,4}$, Baglioni $\mathrm{C}^{1,5}$
${ }^{1}$ Department of Human Sciences, Guglielmo Marconi University, Rome, Italy;
${ }^{2}$ Department of Psychology, University of Bologna, Bologna, Italy;
${ }^{3}$ Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;
${ }^{4}$ IRCCS Fondazione Santa Lucia, Rome, Italy;
${ }^{5}$ Department of Clinical Psychology and Psychophysiology/Sleep, Medicine, Centre for Mental Disorders, University Medical Centre, Freiburg, Germany.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest: No potential conflict of interest was reported by the authors.

Acknowledgements: We are grateful to the authors who kindly responded to requests for study information.

## Author address for correspondence:

Meneo Debora

Department of Human Sciences, Guglielmo Marconi University, Via Plinio, 44-00193 Rome, Italy

E-mail address: d.meneo@unimarconi.it (D. Meneo)

## Summary

Young adults (18-30 years) are vulnerable to sleep-wake disturbances and substance use, which are bi-directionally associated. The present work aims to organise the literature that deals with the association between sleep and substance use in young adults, also considering self-medication behaviours.

We adopted a framework that accounts for the multidimensionality of sleep and the effect of different substances. We considered sleep disturbances (insomnia symptoms, sleep quality), sleep health dimensions (duration, satisfaction, efficiency, timing, daytime alertness), circadian characteristics (chronotype). Substances were alcohol, caffeine, nicotine, cannabis, others. We included 46 studies. The use of caffeine and nicotine was associated with higher odds of sleep disturbances. No significant effect was detected for sleep duration. In narrative findings, daytime dysfunction was associated with alcohol and caffeine use, and poor sleep satisfaction with nicotine use. Few evidence were available for the other sleep health dimensions. Evening chronotype was associated with alcohol, caffeine, and nicotine use. Few studies focused on cannabis or selfmedication. Longitudinal results were inconclusive.

We found a distinct pattern of associations between different substances and different sleep outcomes. Further investigation considering the multidimensionality of sleep would create a better understanding of the complex relationship between substance use and sleep health in young adults.

Keywords: meta-analysis; insomnia; sleep health; substance use; self-medication; young adults

## 1. Introduction

Insufficient sleep and insomnia symptoms are common complaints in adults worldwide, with high individual and societal costs [1]. Around $30 \%$ of healthy adults are frequently unsatisfied with their sleep, one third sleeps less than the recommended 7 hours [2], and one in ten suffers from insomnia disorder [3]. Young adults (18-30 years) are particularly vulnerable to sleep problems: throughout this developmental period, sleep duration decreases and insomnia incidence increases [4,5]. College students appear at risk for sleep disturbances, with up to $60 \%$ complaining of poor sleep quality [6]. On the other hand, there are reports of higher odds of insufficient sleep among noncollege and working young adults $[7,8]$. Overall, $10-30 \%$ of young adults meet the criteria for chronic insomnia [9,10]. Parallel to the increase in sleep difficulties, there is an increase in substance use throughout young adulthood [11,12]. Illicit drug use is often initiated between 18 and 25 years of age [13]. During this time period, there is also an increase in the use of alcohol and caffeinated products [13]. Neurobiological findings indicate that psychoactive substances disrupt sleep-wake regulation systems [14]. On the other hand, sleep-wake disturbances affect the course of substance use disorder [15]. Longitudinal data indicates that the pattern of substance use is predicted by sleep and circadian characteristics, such as late chronotype (eveningness) and sleep timing [16,17], sleep duration [17,18,19], daytime sleepiness [19], and insomnia symptoms [20]. On the other hand, sleep health is predicted by substance use, including alcohol [20], nicotine [17,21], and cannabis [17]. One proposed underlying mechanism for this bi-directional association is self-medication: the experience of sleepwake difficulties may prompt the use of sleep promoting substances [22]. Similarly, the experience of non-restorative sleep can encourage the use of wake-enhancing substances to overcome daytime sleepiness [23]. Among young adults, $10-15 \%$ use alcohol or cannabis as sleep aids [6,24] and 15$25 \%$ report using stimulant beverages to counter insufficient sleep or to relieve fatigue [23]. Both sleep-inducing and wake-enhancing substances are associated with sleep impairment [25]. A further deterioration of sleep may then increase the need to self-medicate, creating a vicious circle [6]. This
may further increase the risk of incurring the negative effects of sleep and substance use problems on mental health [26,27,28].

It is important to understand how sleep-wake disturbances and substance use influence each other during young adulthood. The literature poses difficulties in disentangling sleep and circadian characteristics associated with substance use. Self-reported poor sleep quality and insomnia symptoms have been associated with a pattern of substance use [29]. Other aspects of sleep, most notably sleep duration and daytime alertness, are also associated with substance use [14]. The multidimensionality of sleep needs to be considered in order to better understand the impact of substance use. Buysse [30] proposed a definition of sleep health that entails a) subjective sleep satisfaction; b) the ability to maintain alert wakefulness during the day; c) appropriate timing of sleep in the 24 -hour cycle; d) the ability to fall asleep or return to sleep easily (efficiency); e) ageappropriate sleep duration. To our knowledge, no systematic review and meta-analysis has appraised the association between the use of different substances and sleep health dimensions, sleep-wake disturbances, and circadian characteristics in young adulthood. The present systematic review and meta-analysis aims to organise and synthesize the evidence on the relationship between sleep-wake dimensions and substance use in a restricted age group (18-30 years). The synthesis is guided by a framework that accounts for the specificity of both sleep dimensions and substances. The framework includes sleep difficulties, sleep health as a multidimensional construct, and circadian characteristics, as well as the effects of different substances (see Figure 1 for a graphic display). Furthermore, the contribution of self-medication in the association between substance use and sleep is also considered.

Following the framework adopted, we will comprehensively assess evidence regarding the following aspects:

1) the association between substance use and a) sleep-wake disturbances, b) sleep health dimensions, c) circadian characteristics
2) the bi-directional longitudinal association between substance use and sleep
3) the association between substance use with the purpose of promoting sleep or enhancing wakefulness and sleep.

## 2. Methods

The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [31] and pre-registered in the PROSPERO database (ID: CRD42022359727). The PRISMA checklist is available as Supplementary File S1.

### 2.1.Study selection

Study eligibility was assessed using the Population, Intervention, Comparison, Outcomes and Study design (PICOS) approach [32]. PICOS is a structured approach for framing questions using five components: the patient population or the disease being addressed $(\mathrm{P})$, the interventions or exposure (I), the comparison group (C), the outcome or endpoint (O), and the study design chosen (S).

We adopted the following inclusion criteria:
Population: studies in which participants were between the age of 18 and 30 years (including baseline age in prospective studies), free from mental or medical diagnoses, drawn from the college or non-college population, either unselected or selected for being habitual substance consumers or having sleep impairments. Studies in which participants were drawn from special populations (e.g., army personnel or veterans, pregnant women) were excluded.

Intervention/exposure and outcome: We included studies in which at least one of the following is an outcome and the other an exposure:
a) Recent use of any of the following substances: alcohol, caffeine, nicotine, cannabis, illicit substances, or misuse of prescription medications.
b) Any of the following sleep-wake dimensions subjectively reported: sleep-wake disturbances, sleep health dimensions (duration, satisfaction, efficiency, timing, daytime alertness), circadian characteristics. Objective assessments of sleep variables (e.g., polysomnography, actigraphy) were excluded.

We included studies in which differences in mean, odds ratio, rate ratio, risk ratio, or incidence ratio were reported or were computable from available data.

Comparator: we included studies in which comparisons were made based on substance use or on sleep. Based on substance use, we included the following criteria for comparison: a) various levels of substance consumption, including no consumption compared to any consumption; b) use to self-medicate sleep-wake disturbances compared to other use. Based on sleep, we included the following comparisons: a) above and below a cut-off for sleep impairment; b) various levels of sleep duration, satisfaction, timing, efficiency, or daytime alertness; c) evening chronotype compared to morning and/or intermediate chronotype.

Study design: longitudinal, cross-sectional, case-control, cohort studies
Languages: English, Italian, German, Spanish, French.

When data were not available in the study report, corresponding authors were contacted twice with a direct request; in the case of no response, the study was excluded.

### 2.2.Search procedure

A keyword-based search was performed in July 2022. The searches were run in the electronic databases of PubMed, PsycINFO, and Scopus. We used a combination of terms related to sleep, to
each different substance (see Definition of variables of interest below), and their association (prevalence OR incidence OR frequency OR rate OR epidemiology OR correlation OR determinants OR risk OR association OR relationship). The full search strategy is available in the PRISMA checklist in Supplementary File S1. Reference lists of the retrieved original articles, relevant reviews, and meta-analyses were screened to identify any missing reports. The first author conducted the literature search. The results were uploaded to CITAVI 6 software (https://www.citavi.com). The review team developed test screening questions for an assessment based on inclusion and exclusion criteria. Together, the first and second authors (D.M., V.B.) screened the titles and abstracts yielded by the search against the inclusion criteria, with a weekly appointment to discuss selection process. Decisions were reached by consensus between reviewers. Disagreement and uncertainty were resolved by contacting a third author (C.B.). Final selection of the articles was discussed by the review team.

### 2.3.Data extraction

Data were extracted using a format developed by the review authors under the supervision of a professional statistician (S.C.). Data extraction was discussed with all authors and performed by the first and second reviewers (D.M., V.B.). Any uncertainty about data coding was discussed with a third author (C.B.) until reaching a consensus. We extracted the following: country, demographics of the sample (target population, mean age and standard deviation, age range, gender composition), information on sleep (sleep-wake dimension and relative assessment), information on substance use (type of substance and relative assessment), main findings.

### 2.4. Definitions of the variables of interest

Substance use. Substances included in the keyword-based search of electronic databases were derived from the literature and from two international reports on substance use, the National Survey on Drug Use and Health (NSDUHD), 2020 [13] and the European Drug Report 2021 [33]. From the
literature, we extracted four groups of substances based on their potential sleep-disrupting effect: alcohol, caffeine, nicotine, and cannabis [34,35,36,]. From international reports [13,33], we extracted a group labelled other substances, which included both illicit substances (e.g., cocaine, amphetamines) and controlled drugs (e.g., sedatives, stimulants) (see Supplementary Table S1 for a detailed list). We included assessments of substance use that referred to a specific time frame (from the past year to last week or month) or to current or regular use. We excluded measures of lifetime use because our main purpose was the association between current substance use and sleep. Selfmedication was defined as the motivation to use a substance (e.g., "as a sleep aid"). For our purpose, the use of non-prescribed sleep medications alone was not considered as self-medication. While the term "sleep aid" is often used to indicate self-medication [37], we did not include this definition in absence of a clear elicitation of motivation for use. A similar approach was used for wake-enhancing substances, for which we considered the motivation (e.g., "to promote wakefulness" or "to compensate for lack of sleep") and not the substance itself (e.g., "stimulants"). Indeed, sleep medications and stimulant substances can be used for a variety of reasons, including experimentation [38,39].

Sleep-wake dimensions. Coding of the sleep variables included is reported in Supplementary Table S2. We included the following assessments:

Sleep disturbances: Insomnia symptoms and overall sleep quality assessed using validated multidimensional questionnaires.

Sleep health dimensions:

- Sleep duration: average hours of sleep at night
- Sleep satisfaction: subjective rating of sleep quality, perception of sleep as being refreshing
- Sleep efficiency: ratio between sleep time and time spent in bed
- Sleep timing: bedtime and midpoint of sleep
- Daytime alertness: sleepiness during the day

Circadian characteristics:

- Circadian preference as measured by a validated questionnaire
- Social jet lag as the differences in midpoint of sleep between work/school days and free days


### 2.5.Quality assessment (risk of bias)

The risk of bias assessment was performed independently by the first and second reviewer, with a weekly appointment for discussion. Any doubt was managed through author consensus and disagreements were resolved by contacting a third author (C.B.). For cross-sectional studies, the Appraisal tool for Cross-Sectional Studies (AXIS) was used [40]. This tool is composed of 20 items, with higher scores indicating a lower risk of bias. We considered a score of at least 15 as an overall low risk of bias (high quality). For prospective and case-control studies we used the appropriate version of the Newcastle-Ottawa Scale (NOS) [41]. A higher score indicates a lower risk of bias, with a score of at least 5 indicating low risk (fair quality) [42]. Details can be found in Supplementary File S3.

### 2.6.Meta-analytic calculations and synthesis

Analyses were performed by a professional statistician (S.C.) using SAS Software 9.4 version with SAS/STAT version 14.1 (SAS Institute Inc., Cary, NC, USA) and MetaXL Software program for Meta-analysis in Microsoft Excel. We calculated the odds ratios (ORs) and 95\% confidence intervals (CIs) to estimate the effect size of the association between sleep dimensions and the use of substances. After variable coding, studies were divided by substance investigated and by sleep dimension, following the adopted framework (Figure 1). We further coded the assessment of the two groups of variables (sleep dimensions and substance use). We could then extract the 7 sleep dimensions (sleep disturbances, the five sleep health dimensions, circadian characteristics) and the 5 groups of substances (alcohol, caffeine, nicotine, cannabis, other substances). Data were entered in
meta-analyses based on comparability of the variables considered and of their assessments. Effect sizes were entered into meta-analysis for each sleep dimension and substance. Therefore, one study could enter in multiple meta-analyses based on the number of substances and sleep dimensions reported. Firstly, meta-analyses were conducted by pooling the ORs of the substances presented in each study. For studies reporting data regarding more than one substance, we averaged the log odds ratios ( $\operatorname{logOR}$ ) for each substance (logOR of substance $\mathrm{X}+\log \mathrm{OR}$ of substance $\mathrm{Y} /$ No. of non-users) and averaged the standard errors (SE) for each substance (SE of substance $\mathrm{X}+\mathrm{SE}$ of substance Y / No. of non-users); in the case of different reference numbers for ORs, a weighted average was made. We used these metrics to calculate the OR and $95 \%$ CI for the 'use of at least one substance' category for each study. This method reduced the likelihood of artificially narrowing the CIs. Then, separate meta-analyses for each substance and sleep outcome were performed for cases in which at least 3 studies could be included in the model. We used random effect models since we expected heterogeneity in the distribution of ORs. An OR greater than 1 indicated that the sleep outcome was more likely in those reporting substance use. Heterogeneity was tested for each model, using Chisquare tests and $\mathrm{I}^{2}$ metrics. Indications of heterogeneity were noted when the test showed a p -value $<0.20$ and an $\mathrm{I}^{2} \geq 50 \%$. Asymmetry was evaluated using a funnel plot and tested with the LFK index, which provides a quantitative measure to assess the degree of asymmetry [43]. LFK scores within $\pm 1$ indicate 'no asymmetry', those exceeding $\pm 1$ but within $\pm 2$ suggest minor asymmetry, and a score of $> \pm 2$ indicates major asymmetry. All report probabilities ( $p$ value) were two-sided, with a significance level of 0.05 except where otherwise specified.

We did not transform among effect sizes when results were presented as means, to reduce bias due to imprecise estimations. We reported a narrative synthesis of the studies not included in the analyses, describing study characteristics, sample composition, and results of individual studies.

## 3. Results

### 3.1.Study selection

We identified a total of 20755 titles from our database search; prior to screening, 10018 duplicates were removed. Title and abstract screening led to 622 eligible studies. After screening full texts against the inclusion criteria, 44 studies were included. Screening of references yielded 33 additional studies, of which 2 were included. The results of our selection process yielded 46 studies. See Figure 2 for detailed search flow.

Please insert "Figure 2. Flow chart of the study selection process" here

### 3.2.Risk of bias

The judgement of risk of bias (quality scores) according to the appropriate tools for each study design is reported in the last column of Table 1. For details of risk of bias assessment of the studies included see Supplementary File S3. Judgment of low risk of bias was carried out for 26 crosssectional studies (AXIS $>14$ ), 3 prospective studies ( $\mathrm{NOS}>4$ ), and 3 case-control studies (NOS $>4$ ).

### 3.3.Study characteristics

Table 1 reports the descriptive characteristics of the included studies divided by study design and sampling. The selection process yielded 36 cross-sectional [44-79], 4 case-control [80-83], and 6 prospective studies [84-89]. In total, 7 studies recruited participants who had been selected due to their use of substances and 39 had samples drawn from the general population. We refer to them as selected and unselected samples, respectively. Prior to data analysis and synthesis, we organised the literature based on study design and sampling (Figure 3). For the rest of the review, we will follow this classification. Sample composition was heterogeneous. Most studies were carried out among college students $(\mathrm{n}=43)$ and had a sample in the age range of $18-25$ years $(\mathrm{n}=26)$. Gender ratio was mostly balanced, with females representing at least half the sample. The sleep dimensions and
substances investigated are reported in Table 1. Some studies reported more than one sleep dimension in association with more than one substance. In most cases, the Pittsburgh Sleep Quality Index (PSQI) [90] was used. In accordance with our data coding, we extracted the following PSQI components: subjective sleep quality (sleep satisfaction), sleep duration, sleep efficiency, daytime dysfunction. The most often-reported sleep assessment was sleep disturbances ( $\mathrm{n}=25$ ), followed by sleep duration ( $\mathrm{n}=17$ ). Circadian characteristics regarded only chronotype ( $\mathrm{n}=7$ ), while none of the included studies assessed social jetlag or circadian rhythm disorders. Meta-analysis could only be performed on sleep disturbances assessed using the PSQI and on sleep duration, due to a high variability in the assessment of other sleep outcomes among a smaller number of studies.

> Please insert "Table 1. Descriptive characteristics of included studies by study design and sampling" here

Please insert "Figure 3. Literature organisation" here
3.4.Cross-sectional association between substance use and sleep

### 3.4.1.Sleep disturbances

Table 2 reports the characteristics and main findings from each of the included studies, divided by study design and samples. A total of 19 cross-sectional studies on unselected samples assessed sleep disturbances in association with alcohol $(\mathrm{n}=8)$, caffeine $(\mathrm{n}=10)$, nicotine $(\mathrm{n}=11)$, cannabis $(\mathrm{n}=1)$, and other substances $(\mathrm{n}=1)$.

Please insert "Table 2. Characteristics and main findings of studies on sleep disturbances, divided by study design and sample" here

Because sleep disturbances were mostly assessed using the PSQI ( $n=14$ ), we performed metaanalytic computations on 10 [46,47,51,52,55,57,62,68,71,74] studies reporting odds based on the total score. The forest plot of the random-effect model for use of at least one substance (alcohol, caffeine, and/or nicotine) is available in Supplementary File S4. Results showed that the use of any substance was associated with 1.38 higher odds of reporting a sleep disturbance ( $95 \%$ CI: 1.20-1.59). No asymmetry (publication bias) was detected (LFK-index: .26; See Supplementary File S4). As expected, there was heterogeneity $\left(\mathrm{Q}=15.97, \mathrm{df}(\mathrm{Q})=9, \mathrm{p}=0.07 ; \mathrm{I}^{2}=44\right)$.

The forest plots of the random effect models for alcohol (a), caffeine (b), and nicotine (c) are reported in Figure 4.

Please insert "Figure 4. Forest plots" here

Alcohol. The pooled OR for alcohol use was 1.24 ( $95 \%$ CI: 1.01-1.53). Heterogeneity was high ( $\mathrm{Q}=9.93 ; \mathrm{df}(\mathrm{Q})=4 ; \mathrm{p}=.04 ; \mathrm{I}^{2}=60$ ). Studies were homogenous in terms of population (college students) and PSQI cut-off ( $>5$ ). Differences in the assessment of alcohol use did not contribute to heterogeneity. One study with a high risk of bias was removed [51]. Pooled OR of studies with low risk of bias yielded a non-significant association ( $\mathrm{OR}=1.16 ; 95 \% \mathrm{CI}: 0.97-1.38$ ) among nonheterogenous studies $\left(\mathrm{Q}=5.1 ; \mathrm{df}(\mathrm{Q})=3 ; \mathrm{p}=0.2 ; \mathrm{I}^{2}=41\right)$. It is worth noting that two studies found that the odds of suffering from a sleep disturbance were higher with higher levels of alcohol consumption, while the odds were non-significant for moderate consumption [51,57].

Caffeine. The random-effect model for caffeine use was performed after removal of two studies that were outliers [49;51]. Pooled OR showed an effect size of 1.69 ( $95 \%$ CI: 1.40-2.03) with no indication of heterogeneity $\left(\mathrm{Q}=3.73 ; \mathrm{df}(\mathrm{Q})=3 ; \mathrm{p}=0.29 ; \mathrm{I}^{2}=19\right)$. In one study, higher consumption of caffeine was associated with higher odds of sleep disturbances [51].

Nicotine. Pooled OR for the 7 studies on current nicotine use was 1.35 ( $95 \%$ CI: 1.14-1.61) with moderate heterogeneity $\left(\mathrm{Q}=13.62 ; \mathrm{df}(\mathrm{Q})=6 ; \mathrm{p}=0.03 ; \mathrm{I}^{2}=56\right)$. Sample composition did not contribute to heterogeneity, as removing one study on the general population [55] did not affect statistics. Sensitivity analysis showed that, after removing one study at a time, results were robust. The major contributor to heterogeneity was one study with a high risk of bias [62]. The remaining studies yielded a pooled OR of $1.22(95 \% \mathrm{CI}: 1.23-1.63)$ and were not heterogenous $(\mathrm{Q}=7.12 ; \mathrm{df}(\mathrm{Q})=$ 5; $p=0.2$ ).

Major asymmetry (publication bias) was detected only for nicotine (LFK-index: 2.31).

Narrative findings. Among the cross-sectional studies on unselected samples that were not included in the meta-analyses, three compared mean substance use between those above and below the PSQI cut-off for sleep disturbances $[56,63,73]$ and four used different sleep assessments [58,64,67,70]. Three studies were on selected samples [77,78,79] and three were case-control studies [80,81,82].

Alcohol use and heavy episodic drinking were found to be more frequent in college students with sleep disturbances [56,63]. One study found that students who consumed more alcohol also had a higher rate of sleep disturbances [64]. Studies on selected samples of alcohol consumers did not find a significant association between sleep disturbances and pattern of alcohol consumption, either measured with retrospective questionnaires [78] or via daily diaries [79]. A significant association was found between sleep disturbances and excessive drinking, defined as a frequency of at least 12 drinks in a single sitting [78].

The association between caffeine use and sleep disturbances was generally confirmed in studies that were not included in the meta-analysis. Caffeine use from any source was associated with a higher occurrence of sleep disturbances in 6 studies, both in college $[46,58,63,64]$ and non-college samples [70,74]. The total PSQI score was found to be associated with lower coffee consumption in one study [73]. This result should be considered in light of the low number of college students scoring
above cut-off for sleep disturbances ( $\mathrm{n}=35$ ). Individual studies considering the source of caffeine revealed mixed findings. In one study, the consumption of both coffee and energy drinks was associated with sleep disturbances [64]. One study found that sleep disturbances were associated with a higher consumption of coffee but not of energy drinks during the evening [63]. On the contrary, Mendoza et al. [58] found that higher insomnia symptoms were associated with energy drink use but not with coffee consumption in college students. Results from Young et al. [74] on a non-college sample confirmed that a greater use of energy drinks is associated with a higher PSQI score. Another study on young adults who were not college students found insomnia symptoms to be associated with the consumption of energy drinks in females but not in males [70].

Studies that were not included in the meta-analysis were non-concordant regarding the association between nicotine use and sleep disturbances. One study found that smokers had higher odds of presenting clinical insomnia symptoms [67], while in another study sleep disturbances were not associated with smoking status [64]. Two case-control studies comparing college students who were current smokers to those who were non-smokers found no significant difference in the PSQI total $[80,81]$. In a study on smokers, the odds of experiencing a sleep disturbance increased with the number of cigarettes smoked [77].

Cannabis use was not cross-sectionally associated with sleep disturbances in one study [64]. In a case-control study, Conroy et al. [82] found that daily use was associated with increased sleep disturbances compared to non-daily use and non-use. Sleep disturbance occurrence was associated with higher odds of consuming illicit substances both in unselected college students [56] and among students selected for excessive drinking [78].

### 3.4.2. Sleep duration.

9 cross-sectional studies on unselected samples assessed sleep duration in association with alcohol $(\mathrm{n}=4)$, caffeine $(\mathrm{n}=5)$, nicotine $(\mathrm{n}=5)$, and other substances $(\mathrm{n}=1)$. Characteristics and main
findings are reported in Table 3. Meta-analyses were performed on 7 studies [45,47,51,54,57,59,61] reporting the odds ratio for short sleep duration classified as $<7$ hours, uniformly with the National Sleep Foundation recommendations.

> Please insert "Table 3. Characteristics and main findings of studies on each sleep health dimension, divided by study design and sample" here

The random effect meta-analytic models for use of alcohol, caffeine, and/or nicotine revealed a high level of heterogeneity $\left(\mathrm{Q}=30.54 ; \mathrm{df}(\mathrm{Q})=6 ; \mathrm{p}<0.001 ; \mathrm{I}^{2}=80\right)$ and minor asymmetry (LFK-index: 1.05). The forest plot is available in Supplementary Figure S4. The pooled estimate was $1.44(95 \%$ CI: 1.08-1.91). Forest plots for models considering each substance are reported in Figure 5. High heterogeneity was detected for alcohol $\left(Q=30.08 ; \operatorname{df}(Q)=3 ; p=0.00 ; I^{2}=90\right)$, caffeine $(Q=16.57$ $\left(\mathrm{df}(\mathrm{Q})=2 ; \mathrm{p}=0.00 ; \mathrm{I}^{2}=88\right)$, and nicotine use $\left(\mathrm{Q}=43.28\left(\mathrm{df}(\mathrm{Q})=4 ; \mathrm{p}=0.00 ; \mathrm{I}^{2}=91\right)\right.$.

Please insert "Figure 5. Forest plots" here

Alcohol. The pooled effect size was 0.95 ( $95 \%$ CI: $0.69-1.31$ ) for alcohol use. Sample composition and risk of bias did not affect heterogeneity. Two studies also reported the odds for level of use. High but not moderate alcohol consumption was significantly associated with shorter sleep duration compared to non-use in one study ( $\mathrm{OR}=1.74 ; 95 \% \mathrm{CI}$ : 1.07-2.81) [51]. In Lohsoonthorn et al. [57], moderate but not high consumption was associated with lower odds of reporting short sleep compared to non-use ( $\mathrm{OR}=0.75 ; 95 \% \mathrm{CI}: 0.62-0.90$ )

Caffeine. In terms of caffeine, one study was removed at the beginning for being an outlier [51]; the pooled effect size was 1.55 ( $95 \%$ CI: $0.94-2.54$ ). One study provided odds based on quantity of use: a higher daily consumption was associated with higher odds of short sleep duration [51]

Nicotine. The model for nicotine use showed a pooled OR of 1.47 ( $95 \%$ CI: $0.85-2.54$ ). One study was identified as a major contributor to heterogeneity [57]. After its removal, the pooled OR
was 2.10 ( $95 \%$ CI: 1.92-2.28), with a $Q-$ value of $1.75(\mathrm{df}(\mathrm{Q})=3 ; \mathrm{p}=0.63)$. Only one study assessed range of consumption [51]: the number of cigarettes per day was not associated with sleep duration. Nonetheless, a low number of high consumers ( $>10$ cigarettes per day; $\mathrm{n}=29$ ) limits the interpretation of this result.

Major asymmetry was observed for alcohol (LFK: -4.68), caffeine (LFK: 4.53), and nicotine (LFK: -4.44).

Narrative findings. Three studies not included in the meta-analyses compared average hours of sleep duration in those consuming a substance and those who were not consumers [45,47,74]. One study was on a sample selected for using either alcohol or cannabis [75] and two were case-control studies [81,83]. In a case-control study, Rusnac et al. [83]. Compared college students reporting only sleep deprivation ( $<7$ average sleep hours) to those reporting chronic insomnia and to a group with sufficient sleep. Students with sleep deprivation alone consumed significantly more drinks per week than those with sufficient sleep and those with insomnia.

Regarding caffeine use, two studies on unselected samples, that were not included in the metaanalysis, found that consumers of energy drinks slept significantly less than non-consumers [45,74]. Those sleeping less than 7 hours consumed significantly more coffee than those with at least 7 hours of sleep [74]. Among alcohol consumers, caffeine consumption or smoking status were not associated with sleep duration [75].

No observational study analysed cannabis use in association with sleep duration, while two studies assessed stimulant medication misuse. Short sleep duration was not associated with the use of either prescribed or non-prescribed stimulant medications, in a sample of college students [72]. A significant association was found in a sample of college students selected for consuming alcohol [75].

### 3.4.3. Narrative findings for other sleep-wake dimensions

Results regarding other dimensions of sleep health besides sleep duration, as defined by Buysse [30], are presented in Table 3. Overall, 4 studies investigated sleep satisfaction [47,65,74,75], 5 examined sleep efficiency [47,51,57,74,75], 4 looked at sleep timing [53,61,66,76], and 8 focused on daytime alertness [47,48,51,57,69,70,74,82].

Sleep satisfaction. Sleep satisfaction was defined as the rate of overall sleep quality through the PSQI component $(\mathrm{n}=3)$ and as the number of restful nights $(\mathrm{n}=1)$. Results did not indicate a robust association with substance use, with the exception of nicotine use. One study assessed alcohol use in association with frequency of restful sleep, finding no association [65]. Results regarding caffeine and nicotine indicate that stimulant use affects sleep satisfaction: smokers were more likely to have frequent nights of unrestful sleep [65] and low sleep quality rating [47). Lower PSQI-derived sleep satisfaction was associated with energy drink use in a sample of young adults [74]. Among alcohol consumers, smoking status was associated with lower sleep satisfaction [75]. In the same sample, the misuse of stimulant medication was not associated with sleep satisfaction [75].

Sleep efficiency. Five studies analysed the association between sleep efficiency as assessed through PSQI and the use of alcohol $(\mathrm{n}=2)$, caffeine $(\mathrm{n}=4)$, nicotine $(\mathrm{n}=4)$, and other substances $(\mathrm{n}=1)$. Sleep efficiency was not found to be associated with alcohol use in college students [51,57]; nor was with caffeine use in young adults who attended college and those who did not [51; 57,74,75]. Nicotine use was not associated with sleep efficiency either [47,57], although one study found that current smokers had double the odds of reporting low sleep efficiency [51]. In a sample of alcohol consumers, both the number of cigarettes per day and use of other substances were associated with low sleep efficiency [75].

Sleep timing. The four studies reporting sleep timing were heterogenous in terms of sample composition, assessment of sleep timing and substances investigated (see Table 2). They all found significant associations between substance use and sleep timing, although in one study no association was detected for coffee use [53]. Hug et al. [53] found that diary-reported alcohol use was higher in
young adults not attending college who had a later midpoint of sleep [53]. DeMartini \& Fucito [76] reported that among college students selected for excessive alcohol use those with a late bedtime also showed a higher alcohol consumption than those with an earlier bedtime. One study assessed bedtime in association with the use of coffee and energy drinks [61], finding that those who had the latest bedtimes ( $>12: 30 \mathrm{am}$ ) were more likely to be energy drink consumers ( $\mathrm{PR}=1.83 ; 95 \% \mathrm{CI}: 1.10-2.55$ ) and to consume more caffeinated beverages ( $p<0.05$ ). Nicotine use in college students [66] was found to be associated with a later midpoint of sleep. The latter result is limited by the small number of smokers ( $1.3 \%$ of the sample). Cannabis and other substance use was not investigated in relation to sleep timing.

Daytime alertness. A total of 8 observational studies investigated the effect of substance use on daytime dysfunction (low levels of alertness), 4 of which were performed on college students. Three studies assessed the outcome using the ESS and four using the PSQI (see Table 2 for details). Across three studies, alcohol use was associated with higher prevalence of daytime dysfunction $[51,57,69]$. Results on caffeine were robust, with the exception of one study that found no association with energy drink consumption in a non-college sample [74]. The use of caffeinated drinks was associated with daytime dysfunction, measured with the PSQI component in college students [51,57] and with the ESS in non-college samples [48;69;70]. Tran et al. (2014) found that the use of energy drinks, but not coffee, was associated with ESS scores. One report indicates a gender effect: the frequent use of energy drinks was associated with a higher level of sleepiness in females but not in males [70]. The four studies assessing nicotine use found no association with daytime dysfunction [47,51,57,69]. Lohsoonthorn et al., [57] found an effect of demographics: after adjusting for age and sex, current smokers had higher odds of experiencing daytime dysfunction (AOR: 1.43; 95\% CI: 1.02-1.98).

Table 4 reports characteristics and main findings of the 5 observational studies investigating chronotype in connection to alcohol $(\mathrm{n}=3)$, caffeine $(\mathrm{n}=3)$, nicotine $(\mathrm{n}=3)$, and cannabis $(\mathrm{n}=1)$. All studies used either the full or reduced version of the MEQ. Eveningness was found to be consistently associated with substance use across studies. Evening-types consumed on average more alcoholic drinks than morning- and intermediate-types [44], and those consuming alcohol were more likely to be evening-types $[60,69]$. Evening-types also consumed significantly more caffeine than morningtypes $[44 ; 50]$ and those consuming caffeine, either as coffee or energy drinks, were more likely to be evening-types [69]. Nicotine use was also associated with eveningness, both in terms of cigarettes smoked [44] and of smoking status $[60,69]$. Only one study assessed cannabis use: in a case-control design, no differences in MEQ score were observed between daily users, non-daily users, and nonusers [82].

Please insert "Table 4. Characteristics and main findings of studies regarding chronotype, divided by study design" here

### 3.5.Longitudinal association between substance use and sleep

Table 5 reports characteristics and main findings of prospective studies, divided in terms of unselected ( $\mathrm{n}=4$ ) and selected ( $\mathrm{n}=2$ ) samples of college students. Sleep was longitudinally assessed in relation to alcohol $(\mathrm{n}=5)$ and cannabis $(\mathrm{n}=3)$ use. Two studies assessed the use of alcohol and/or cannabis as sleep aids.

Please insert "Table 5. Details and main findings of prospective studies on unselected (a) and selected (b) samples." here

Prospective data indicates that alcohol use plays a role in subsequent sleep health outcomes [85,87] and sleep timing has an effect on subsequent alcohol use [84]. In a study by Liu et al. [85], college students were monitored from their last semester throughout the period of their first full-time employment. The authors found that the stability of their drinking profile was associated with sleep satisfaction at 12 -month follow-up. That is, those who remained in the high-risk drinking profile had lower sleep satisfaction compared to those who had transitioned to a moderate-risk profile. The authors concluded that the reduction of alcohol consumption was associated with better sleep outcomes [85]. Samek \& Akua [86] observed 167 college students for 4 years from their first year of enrolment, assessing the frequency of their alcohol and cannabis use and average sleep duration during the previous month. Results based on unpublished data indicated that substance use did not predict sleep duration at follow-up. Van Reen et al. [87] monitored sleep and alcohol consumption of college students through their first 9 weeks of admission through the medium of daily diaries. Data showed that in this period, students consuming alcohol had later bedtimes across the week compared to non-consumers. In an accelerated longitudinal design, Hasler et al. [84] observed a significant effect of sleep timing and circadian characteristics on alcohol use: greater eveningness ( $O R=1.30$; $96 \%$ CI: 1.08-1.54) and a later midpoint of sleep ( $\mathrm{OR}=1.32 ; 96 \% \mathrm{CI}: 1.12-1.56$ ) were associated with higher odds of showing a more severe heavy drinking pattern the following year. Sleep duration, sleep satisfaction, and daytime dysfunction were not significantly associated with pattern of alcohol consumption [84]. Goodhines et al. [88] adopted 14-day daily diaries to perform an EMA study on college students selected for using either alcohol or cannabis. Results showed that days of greater alcohol consumption were associated with a poorer sleep quality that night and a shorter sleep duration [88]. Across three studies, non-significant longitudinal and daily associations were found for cannabis use $[84,86,88]$.

### 3.6. Use of alcohol and cannabis as sleep aids

One longitudinal [89] and one EMA [88] study found significant concurrent associations between cannabis and/or alcohol use as a sleep aid and sleep outcomes in selected samples of college students. At baseline, $25 \%$ [89] to $38 \%$ [88] reported using cannabis and/or alcohol as a sleep aid. $14 \%$ [89] to $29 \%$ [88] reported that they took over-the-counter medications as sleep aids. In both samples, sleep aid users had a higher occurrence of sleep disturbances (ISI) compared to non-sleep aid users. Regarding sleep health dimensions, one study found that sleep-aid users had lower sleep satisfaction and a shorter sleep duration compared to non-sleep aid users [88]. The results were not replicated in the study by Goodhines et al. [89] and no association with chronotype emerged.

EMA data indicates a daily association between sleep aid use and lower sleep satisfaction, but no effect on sleep duration or daytime fatigue as assessed through sleep diaries [88]. In within-person analysis, days of cannabis use as a sleep aid, but not alcohol, were associated with a shorter sleep duration and daytime fatigue. The reverse effect was non-significant: sleep-wake variables were not associated with subsequent sleep aid use or substance use. Longitudinal data from Goodhines et al. [89] showed a persistence of sleep aid use at the 68-day follow-up: $63 \%$ of T1 sleep aid users and $19 \%$ of T1 non-sleep aid users reported using alcohol and/or cannabis to aid sleep at T2. The initiation was not associated with any sleep variables at baseline or at follow-up. Longitudinal data did not show a significant predictive role of sleep aid use on sleep disturbances, sleep health dimensions or chronotype.

## Discussion

In our synthesis, we considered the association between different substances and different sleep dimensions. We adopted a framework accounting for sleep disturbances, Buysse's [30] sleep health dimensions (sleep duration, efficiency, satisfaction, timing, daytime alertness), and chronotype. Sleep dimensions were assessed in association with the most used substances among
young adults: alcohol, caffeine, nicotine, cannabis, other substances. This multidimensional view on sleep revealed a distinctive pattern of associations.

Meta-analytic results were robust and showed that young adults consuming caffeine and nicotine have higher odds of reporting a sleep disturbance. Evidence on sleep duration suggest an association with alcohol consumption, but meta-analytic findings were inconclusive. Sleep satisfaction appears to be associated only with nicotine use, although there were few studies concerning this point. Sleep efficiency was not consistently associated with substance use. The few studies on sleep timing suggest that this dimension is associated with substance use both crosssectionally and prospectively. Daytime dysfunction (low levels of alertness) was consistently associated with alcohol and caffeine consumption. Eveningness was associated with alcohol, caffeine, and nicotine use. Few studies investigated cannabis use, and only one found association between daily use and sleep disturbances. Both alcohol and cannabis used as a sleep aid were cross-sectionally associated with sleep disturbances and poorer sleep health. Prospective data were scarce and suggested that sleep timing and chronotype may be longitudinally associated with alcohol use, but further investigations are needed.

The association found between sleep-wake dimensions and the use of alcohol, caffeine, and nicotine are in line with polysomnographic findings that attest to their sleep-disrupting effect [34]. Our narrative findings indicate that young adults who experience sleep problems also report higher alcohol consumption. Meta-analytic results did not robustly indicate higher odds of sleep disturbances in alcohol consumers. Together, these mixed results may be accounted for by a dose-dependent effect of alcohol on sleep [91]. Indeed, the consumption of alcohol at high doses suppresses slow-wave sleep and REM sleep and leads to complaints of unsatisfactory sleep [91]. It is possible that a dichotomous classification (alcohol use vs. non-use) is not sensitive enough to detect associations in a population in which alcohol use is common. In the pool of included studies, from 30 to $80 \%$ of samples were habitual alcohol consumers. Furthermore, sleep disturbances are prevalent in heavy-
drinking college students [78,79]. The effect of alcohol consumption on sleep health is not clear. In our synthesis, significant associations were found with both short and long sleep durations. This may be partially due to the sedating effect of alcohol at low doses, which leads to greater sleepiness and a longer sleep duration [14]. The timing of sleep is an important factor to consider. When a later bedtime is associated with an early academic or work schedule, it is difficult to obtain the recommended 7 hours of sleep. The studies included suggest that alcohol use is associated with sleep timing, daytime dysfunction, and eveningness. It is possible that a later sleep timing and/or circadian preference are associated with higher levels of psychophysiological activation in the evening, which may lead to a greater consumption of alcohol as a sedating agent [44]. A higher level of activation may also encourage participation in evening social events in which alcohol is mostly consumed, thus postponing sleep timing.

In our synthesis, we showed that higher caffeine use was associated with sleep disturbances, high daytime dysfunction, and eveningness. Caffeine is a wake-promoting agent that, in high doses or with chronic use, may disrupt the sleep-wake regulation system and lead to subjective complaints of poor sleep quality, reduced sleep duration, and high daytime sleepiness [34]. Meta-analytic results for sleep disturbances were robust, and no heterogeneity was detected. This result was also generally supported by studies not included in the meta-analysis. Differences emerged in two individual studies that investigated the use of coffee and energy drinks separately. Investigations into sources of caffeine are warranted, as brands of energy drinks highly differ in terms of other possible sleep-disturbing additives, such as sugar [92]. Furthermore, in accordance with sleep hygiene practices, the time of consumption could also enhance the negative effect of caffeine on sleep [63]. Contrary to the literature [35], caffeine use was not consistently associated with short sleep duration ( $<7$ hours). This may suggest that a cut-off of sleep duration is not sensitive enough to detect significant differences among young adults. In fact, sleep duration was generally short ( $<7$ hours) in the included studies. Nevertheless, the few studies comparing mean hours suggest that caffeine consumers may sleep fewer
hours than non-consumers. The association between daytime dysfunction and caffeine use was expected, based on the literature [35]. A higher level of sleepiness during the day is often associated with an attempt to overcome the drowsiness by consuming more caffeine. On the other hand, a high caffeine intake leads to sleep disturbances, which in turn lead to high daytime dysfunction. Across studies, the association between chronotype and caffeine consumption was robust. Caffeine products, in particular coffee, are most often consumed in the first half of the day, when levels of alertness in evening-types are lower than in morning-types [44]. It is plausible that a greater need for energy in the morning is partially responsible for the association between eveningness and caffeine.

Our findings showed that young adults who were smokers were more likely to report sleep disturbances, low sleep satisfaction, and an evening preference. The stimulating effect of nicotine, together with the sleep-disrupting effect of cravings at night, are among the mechanisms involved in the association between sleep disturbances and both chronic smoking and acute nicotine administration [34]. Nonetheless, two case-control studies suggested that among smokers selfreported sleep disturbances are non-concordant with physiological indices [80,81]. The absence of significant differences in subjective assessment may be due to the instrument employed. While the PSQI is a validated assessment of sleep disturbances with sound psychometric properties, the external validity of each component is more problematic [93]. This may be of relevance for subjectivelyreported sleep efficiency, which was not found to be associated with any substance use.

In our systematic review and meta-analysis, the few studies included that investigated cannabis use found no consistent association with sleep. One case-control study showed that the frequency of use is an important factor to consider [82]. After an initial sleep-promoting effect of cannabis, frequent use rapidly leads to tolerance and, with chronic use, the negative impact on sleep architecture increases [36]. The long-term effect of cannabis use in young adults is not clear. Prospective data does not support a predictive effect of cannabis use on sleep [86,88] or of sleep dimension on cannabis use [84]. A longitudinal association has been found in studies performed from
adolescence to young adulthood [11]. How the relationship between cannabis use and sleep problems evolves during young adulthood needs further investigation.

A functional perspective should also be considered: the experience of sleep-wake disturbances may prompt self-medication with sedating and stimulating substances. Self-medication has been found to be bi-directionally associated with sleep disturbances [94]. Although we had planned to carry out a focused synthesis on self-medication, data could be derived from only two of the included studies $[88,89]$. Self-medication was found to be prevalent and persistent among college students who consume alcohol and/or cannabis. A concurrent association between sleep aid use and sleep disturbances was reported. Nonetheless, longitudinal data did not support a prospective association at two-month follow-up. A longer follow-up period may be needed to detect the possible long-term effects of sleep aid use on sleep. This is of particular concern among college students, as recent evidence indicates that the phenomenon is becoming embedded in the college culture [95]. No included study assessed the specific motivation for use of stimulants in association with sleep-wake outcomes. Wake-enhancement is among the most common of motivations for caffeine use [23]. This may also explain the higher consumption of stimulants among evening-types. It has been suggested that sedative use and stimulant use have different functional roles in evening-types: alcohol allows for relaxation in the evening when energy levels of evening-types are still high; stimulants, on the other hand, help counteract sleepiness early in the day [44]. Taking these initial findings together, the motivation for using a substance as sleep- or wake-enhancer needs to be further considered.

Another explanation for the associations found could be that poor sleep health and consumption of substances are concurrently associated in the context of unhealthy lifestyles. Alcohol, caffeine, and nicotine consumption in the evening is a poor sleep hygiene practice that is common among young adults [96]. Younger adults have a worse awareness of sleep hygiene compared to older adults, and seldom implement good habits [97]. While the association between sleep disturbances and sleep hygiene has been widely investigated in young people, especially college students [98], less is
known about the association with substance use at bedtime. No study in our synthesis considered the association between sleep hygiene and substance use and their effect on sleep. In an ongoing unpublished study (Meneo et al.), the authors found that the frequency of use of alcohol, nicotine, cannabis, coffee, and other substances in the hour preceding bedtime correlated with sleep hygiene practices and insomnia symptoms. An unhealthy lifestyle and poor attention to sleep hygiene can interact and have negative consequences on sleep health.

## Limitations

The present work is not free of limitations. High heterogeneity was detected, and sensitivity analyses were performed based on sampling and risk of bias. It cannot be excluded that other factors contributed to mixed findings. For instance, cultural factors are the main sources of heterogeneity when analysing substance use, for two main reasons. Firstly, availability and stances towards a substance are highly subject to cultural variability. Secondly, the degree of fidelity of self-reported substance use is tied to the cultural stance toward the specific substance; for example, alcohol use is more likely to be reported in countries without strong social disapproval. A second limitation concerns the generalizability of our results. Most studies were performed on college students, which are more vulnerable to sleep disorders and have sleep-wake habits that may be profoundly different from that of working young adults. Thirdly, our inclusion criteria may have excluded relevant work in the field of substance-sleep interaction. We adopted an aged-based criterion, including studies performed on young adults from age 18 to 30 , following the definition of emerging adulthood proposed by Arnett and colleagues [99]. Nonetheless, young adulthood is defined in some context as extending throughout the 30s. As a consequence, our definition of young adulthood may have excluded other relevant studies, especially regarding the effect of cannabis use. While we considered a plethora of substances and different sleep-wake dimensions, we did not include lifetime use and objective assessment of sleep outcomes; nor did we take other sleep dimensions such as sleep onset
latency and wake after sleep onset into consideration. Furthermore, the applied definition of sleep aid use included a clear reference to motivation for use, and other relevant work on the use of sleep aids may have been excluded. An extensive review on the topic is beyond the scope of the present work, but this area of research may benefit from future attempts to organise and synthetize the literature on the subject.

## Conclusions

A multidimensional view on sleep is useful in order to understand its interaction with substance use in a young population. We noted a lack of literature on most sleep health dimensions, except for sleep duration and daytime sleepiness. Self-medication was also seldom investigated in association with sleep health. Our results showed that the use of alcohol, caffeine, nicotine, cannabis, and other substances was differentially associated with sleep disturbances, sleep health dimensions, and chronotype. We found some mixed results, especially on alcohol use. More investigations are needed to understand the effect of different substances on sleep health dimensions, and the role of motivation for use.

## Practice points

1) The consumption of different substances shows a differential pattern of association with sleep disturbances, sleep health dimensions, and circadian preference in young adults aged 18-30 years
2) The most robust association was between caffeine use and sleep disturbances, while the impact of alcohol and nicotine use needs further investigations in this age group
3) More longitudinal investigations are needed to elucidate how the use of alcohol and/or cannabis as sleep aids may contribute to the effect of these substances on sleep health

## Research agenda

Future research should further enhance our understanding of the relationship between substance use and sleep difficulties in young adults, focusing on the role of self-medication attempts. Prospective data are particularly needed to follow the parallel increase in substance use and sleep disturbances during young adulthood. A multidimensional view on sleep health appears to be useful to capture the effect of substance use on sleep in younger people, and further investigations in this direction are advisable. Psychological and contextual factors may also be explored, as they may be crucial in the process of coping with a sleep problem.

## References

1. Garbarino S, Lanteri P, Durando P, Magnavita N, Sannita WG. Co-Morbidity, Mortality, Quality of Life and the Healthcare/Welfare/Social Costs of Disordered Sleep: A Rapid Review. Int J Environ Res Public Health. 2016;13(8):831. Published 2016 Aug 18. doi:10.3390/ijerph13080831
2. Hirshkowitz, M., Whiton, K., Albert, S. M., Alessi, C., Bruni, O., DonCarlos, L., Hazen, N., Herman, J., Katz, E. S., Kheirandish-Gozal, L., Neubauer, D. N., O'Donnell, A. E., Ohayon, M., Peever, J., Rawding, R., Sachdeva, R. C., Setters, B., Vitiello, M. V., Ware, J. C., \& Adams Hillard, P. J. (2015). National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep health, l(1), 40-43. https://doi.org/10.1016/j.sleh.2014.12.010
3. Baglioni, C., Altena, E., Bjorvatn, B., Blom, K., Bothelius, K., Devoto, A., Espie, C. A., Frase, L., Gavriloff, D., Tuuliki, H., Hoflehner, A., Högl, B., Holzinger, B., Järnefelt, H., Jernelöv, S., Johann, A. F., Lombardo, C., Nissen, C., Palagini, L., Peeters, G., ... Riemann, D. (2020). The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the

European Insomnia Network to promote implementation and dissemination of treatment. Journal of sleep research, 29(2), e12967. https://doi.org/10.1111/jsr. 12967
4. Buysse, D. J., Angst, J., Gamma, A., Ajdacic, V., Eich, D., \& Rössler, W. (2008). Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep, 31(4), 473-480. https://doi.org/10.1093/sleep/31.4.473
5. Maslowsky, J., \& Ozer, E. J. (2014). Developmental trends in sleep duration in adolescence and young adulthood: evidence from a national United States sample. The Journal of adolescent health: official publication of the Society for Adolescent Medicine, 54(6), 691-697. https://doi.org/10.1016/j.jadohealth.2013.10.201
6. Lund HG, Reider BD, Whiting AB, Prichard JR. Sleep patterns and predictors of disturbed sleep in a large population of college students. $J$ Adolesc Health. 2010;46(2):124-132. doi:10.1016/j.jadohealth.2009.06.016
7. Morita, Y., Sasai-Sakuma, T., Asaoka, S., \& Inoue, Y. (2015). Prevalence and Correlates of Insufficient Sleep Syndrome in Japanese Young Adults: A Web-Based Cross-Sectional Study. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 11(10), 1163-1169. https://doi.org/10.5664/jcsm. 5092
8. Tzilos, G. K., Caviness, C. M., Anderson, B. J., \& Stein, M. D. (2016). Stimulant use and associated health risks among student and non-student emerging adults. Emerging Adulthood, 4(4), 298-302. https://doi.org/10.1177/2167696815617077
9. Sivertsen, B., Vedaa, Ø., Harvey, A. G., Glozier, N., Pallesen, S., Aarø, L. E., Lønning, K. J., \& Hysing, M. (2019). Sleep patterns and insomnia in young adults: A national survey of Norwegian university students. Journal of sleep research, 28(2), e12790. https://doi.org/10.1111/jsr. 12790
10. Taylor, D. J., Bramoweth, A. D., Grieser, E. A., Tatum, J. I., \& Roane, B. M. (2013). Epidemiology of insomnia in college students: relationship with mental health, quality of life, and
substance use difficulties. Behavior therapy, 44(3), 339-348. https://doi.org/10.1016/j.beth.2012.12.001
11. Troxel WM, Rodriguez A, Seelam R, et al. Longitudinal associations of sleep problems with alcohol and cannabis use from adolescence to emerging adulthood. Sleep. 2021;44(10):zsab102. doi:10.1093/sleep/zsab102
12. Windle M. Maturing Out of Alcohol Use in Young Adulthood: Latent Class Growth Trajectories and Concurrent Young Adult Correlates. Alcohol Clin Exp Res. 2020;44(2):532-540. doi:10.1111/acer. 14268
13. SAMHSA. The National Survey on Drug Use and Health; 2019 [cited 2022 Jul 6]. Available from: https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables
14. Angarita, G.A., Emadi, N., Hodges, S. et al. Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addict Sci Clin Pract 11, 9 (2016). https://doi.org/10.1186/s13722-016-0056-7
15. Roehrs T, Sibai M, Roth T. Sleep and alertness disturbance and substance use disorders: A bi-directional relation. Pharmacol Biochem Behav. 2021;203:173153. doi:10.1016/j.pbb.2021.173153
16. Hasler BP, Casement MD, Sitnick SL, Shaw DS, Forbes EE. Eveningness among late adolescent males predicts neural reactivity to reward and alcohol dependence 2 years later. Behav Brain Res. 2017;327:112-120. doi:10.1016/j.bbr.2017.02.024
17. Pasch KE, Latimer LA, Cance JD, Moe SG, Lytle LA. Longitudinal bi-directional relationships between sleep and youth substance use. $J$ Youth Adolesc. 2012;41(9):1184-1196. doi:10.1007/s10964-012-9784-5
18. Geoffroy PA, Tebeka S, Blanco C, Dubertret C, Le Strat Y. Shorter and longer durations of sleep are associated with an increased twelve-month prevalence of psychiatric and substance use disorders: Findings from a nationally representative survey of US adults (NESARC-III). $J$ Psychiatr Res. 2020;124:34-41. doi:10.1016/j.jpsychires.2020.02.018
19. Miller MB, Janssen T, Jackson KM. The Prospective Association Between Sleep and Initiation of Substance Use in Young Adolescents. J Adolesc Health. 2017;60(2):154-160. doi:10.1016/j.jadohealth.2016.08.019
20. Hasler BP, Martin CS, Wood DS, Rosario B, Clark DB. A longitudinal study of insomnia and other sleep complaints in adolescents with and without alcohol use disorders. Alcohol Clin Exp Res. 2014;38(8):2225-2233. doi:10.1111/acer. 12474
21. Bilsky SA, Luber MJ, Cloutier RM, Dietch JR, Taylor DJ, Friedman HP. Cigarette use, anxiety, and insomnia from adolescence to early adulthood: A longitudinal indirect effects test. Addict Behav. 2021;120:106981. doi:10.1016/j.addbeh.2021.106981
22. Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev. 2003;7(6):523-539. doi:10.1016/s1087-0792(03)90005-0
23. Malinauskas BM, Aeby VG, Overton RF, Carpenter-Aeby T, Barber-Heidal K. A survey of energy drink consumption patterns among college students. Nutr J. 2007;6:35. Published 2007 Oct 31. doi:10.1186/1475-2891-6-35
24. Taylor DJ, Bramoweth AD. Patterns and consequences of inadequate sleep in college students: substance use and motor vehicle accidents. J Adolesc Health. 2010;46(6):610-612. doi:10.1016/j.jadohealth.2009.12.010
25. Ogeil RP, Phillips JG, Savic M, Lubman DI. Sleep- and Wake-Promoting Drugs: Where Are They Being Sourced, and What Is Their Impact?. Subst Use Misuse. 2019;54(12):1916-1928. doi:10.1080/10826084.2019.1609040
26. Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135(1-3):10-19. doi:10.1016/j.jad.2011.01.011
27. Hertenstein E, Feige B, Gmeiner T, Kienzler C, Spiegelhalder K, Johann A, et al. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. Sleep Med Rev. 2019;43:96-105. doi:10.1016/j.smrv.2018.10.006
28. Esmaeelzadeh S, Moraros J, Thorpe L, Bird Y. Examining the Association and Directionality between Mental Health Disorders and Substance Use among Adolescents and Young Adults in the U.S. and Canada-A Systematic Review and Meta-Analysis. J Clin Med. 2018;7(12):543. Published 2018 Dec 13. doi:10.3390/jcm7120543
29. Kenney SR, Lac A, Labrie JW, Hummer JF, Pham A. Mental health, sleep quality, drinking motives, and alcohol-related consequences: a path-analytic model. J Stud Alcohol Drugs. 2013;74(6):841-851. doi:10.15288/jsad.2013.74.841
30. Buysse DJ. Sleep health: can we define it? Does it matter?. Sleep. 2014;37(1):9-17. Published 2014 Jan 1. doi:10.5665/sleep. 3298
31. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. Published 2015 Jan 2. doi:10.1136/bmj.g7647
32. O'Connor DA, Green SE, Higgins JPT. Defining the review question and developing criteria for including studies. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from: www.training.cochrane.org/handbook.
33. EMCDDA. European Drug Report 2021: Trends and Developments; 2021 [cited 2022 Jul 6]. Available from: https://www.emcdda.europa.eu/publications/edr/trends-developments/2021_en
34. Garcia AN, Salloum IM. Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: A focused review. Am J Addict. 2015;24(7):590-598. doi:10.1111/ajad. 12291
35. Clark I, Landolt HP. Coffee, caffeine, and sleep: A systematic review of epidemiological studies and randomized controlled trials. Sleep Med Rev. 2017;31:70-78. doi:10.1016/j.smrv.2016.01.006
36. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23. doi:10.1007/s11920-017-0775-9
37. Chong Y, Fryer CD, Gu Q. Prescription sleep aid use among adults: United States, 20052010. NCHS Data Brief. 2013;(127):1-8.
38. Ghandour LA, El Sayed DS, Martins SS. Prevalence and patterns of commonly abused psychoactive prescription drugs in a sample of university students from Lebanon: an opportunity for cross-cultural comparisons. Drug Alcohol Depend. 2012;121(1-2):110-117. doi:10.1016/j.drugalcdep.2011.08.021
39. White BP, Becker-Blease KA, Grace-Bishop K. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. $J$ Am Coll Health. 2006;54(5):261-268. doi:10.3200/JACH.54.5.261-268
40. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458. Published 2016 Dec 8. doi:10.1136/bmjopen-2016-011458
41. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available online: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
42. McPheeters ML, Kripalani S, Peterson NB, et al. Closing the quality gap: revisiting the state of the science (vol. 3: quality improvement interventions to address health disparities). Evid Rep Technol Assess (Full Rep). 2012;(208.3):1-475.
43. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195-203. doi:10.1097/XEB. 0000000000000141
44. Adan A. Chronotype and personality factors in the daily consumption of alcohol and psychostimulants. Addiction. 1994;89(4):455-462. doi:10.1111/j.1360-0443.1994.tb00926.x.
45. Al Otaibi HH, Kamel SM. Health-risk behaviors associated with sugar-sweetened beverage consumption among saudi young adults. Biomedical Research (India). 2017; 28(19):84848491.
46. AlSharif SM, Al-Qathmi MS, Baabdullah WM, Alhrkan TA, Fayoumi YA, Alhejaili FF, et al. The Effect of Caffeinated Beverages on Sleep Quality in College Students. Saudi Journal of Internal Medicine. 2018;8(1):43-8. doi:10.32790/sjim.2018.8.1.6
47. Arbinaga F, Fernandez-Cuenca S, Joaquin-Mingorance M. The relationship between subjective sleep quality and smoking in university students. Sleep and Hypnosis. 2019; 21(4):309320.
48. Barbosa SMML, Batista RFL, Rodrigues LDS, et al. Prevalence of excessive daytime sleepiness and associated factors in adolescents of the RPS cohort, in São Luís (MA), Brazil. Prevalência de sonolência diurna excessiva e fatores associados em adolescentes da coorte RPS, em São Luís (MA). Rev Bras Epidemiol. 2020;23:e200071. doi:10.1590/1980549720200071
49. Bin Ismayatim IA, Binti Azhar NH, Islam N, Lail SABMS, Ismail SB. A Cross-sectional Study on Association of Smoking Habits and Insomnia Among University Students in Cyberjaya. Malaysian Journal of Medicine and Health Sciences.2021;17:13-18.
50. Bodur M, Baspinar B, Özçelik AÖ. Do sleep quality and caffeine consumption mediate the relationship between late chronotype and body mass index?. Food Funct. 2021;12(13):59595966. doi:10.1039/d0fo03435e
51. Bogati S, Singh T, Paudel S, Adhikari B, Baral D. Association of the Pattern and Quality of Sleep with Consumption of Stimulant Beverages, Cigarette and Alcohol among Medical Students. J Nepal Health Res Counc. 2020;18(3):379-385. Published 2020 Nov 13. doi:10.33314/jnhrc.v18i3.2633
52. Elwasify M, Barakat DH, Fawzy M, Rashed I, Radwan DN. Quality of sleep in a sample of Egyptian medical students. Middle East Current Psychiatry.2016;23(4):200-207. 10.1097/01.XME.0000490933.67457.d4.
53. Hug E, Winzeler K, Pfaltz MC, Cajochen C, Bader K. Later Chronotype Is Associated with Higher Alcohol Consumption and More Adverse Childhood Experiences in Young Healthy Women. Clocks Sleep. 2019;1(1):126-139. Published 2019 Feb 12. doi:10.3390/clockssleep1010012
54. Kianersi S, Zhang Y, Rosenberg M, Macy JT. Association between e-cigarette use and sleep deprivation in U.S. Young adults: Results from the 2017 and 2018 Behavioral Risk Factor Surveillance System. Addict Behav. 2021;112:106646. doi:10.1016/j.addbeh.2020.106646
55. Liao Y, Xie L, Chen X, et al. Sleep quality in cigarette smokers and nonsmokers: findings from the general population in central China. BMC Public Health. 2019;19(1):808. Published 2019 Jun 24. doi:10.1186/s12889-019-6929-4
56. Liu D, Kahathuduwa C, Vazsonyi AT. The Pittsburgh Sleep Quality Index (PSQI): Psychometric and clinical risk score applications among college students. Psychol Assess. 2021;33(9):816-826. doi:10.1037/pas0001027
57. Lohsoonthorn V, Khidir H, Casillas G, et al. Sleep quality and sleep patterns in relation to consumption of energy drinks, caffeinated beverages, and other stimulants among Thai college students. Sleep Breath. 2013;17(3):1017-1028. doi:10.1007/s11325-012-0792-1
58. Mendoza L, Marco G, Gonzalo CV, Ali AKC, Rosales K. Álvaro A, Chávez R, Bruno S, Alvarado Germán F. Use of energy drinks and insomnia symptoms in medical students from a Peruvian university. Revista Chilena de Neuro-Psiquiatria. 2021;59(4): 289-301. DOI: 10.4067/S0717-92272021000400289.
59. Naito R, Yun Low W, Wan Yuen C. Sleep Deprivation and Its Associated Factors Among Undergraduate Students in Malaysia. Asia Pac J Public Health. 2021;33(5):530-538. doi:10.1177/10105395211019930
60. Nakade M, Takeuchi H, Kurotani M, Harada T. Effects of meal habits and alcohol/cigarette consumption on morningness-eveningness preference and sleep habits by Japanese female students aged 18-29. J Physiol Anthropol. 2009;28(2):83-90. doi:10.2114/jpa2.28.83
61. Ogilvie RP, Lutsey PL, Widome R, Laska MN, Larson N, Neumark-Sztainer D. Sleep indices and eating behaviours in young adults: findings from Project EAT. Public Health Nutr. 2018;21(4):689-701. doi:10.1017/S1368980017003536.
62. Orsal O, Orsal O, Alparslan GB, Unsal A. Evaluation of the relation between quality of sleep and anxiety among university students. HealthMED. 2021;6(7):2244-2255.DOI: Cited.
63. Pham HT, Chuang HL, Kuo CP, Yeh TP, Liao WC. Electronic Device Use before Bedtime and Sleep Quality among University Students. Healthcare (Basel). 2021;9(9):1091. Published 2021 Aug 24. doi:10.3390/healthcare9091091
64. Riera-Sampol A, Rodas L, Martínez S, Moir HJ, Tauler P. Caffeine Intake among Undergraduate Students: Sex Differences, Sources, Motivations, and Associations with Smoking Status and Self-Reported Sleep Quality. Nutrients. 2022;14(8):1661. Published 2022 Apr 16. doi:10.3390/nu14081661
65. Rosso AC, Wilson OWA, Papalia Z, Duffey M, Kline CE, Bopp M. Frequent restful sleep is associated with the absence of depressive symptoms and higher grade point average among college students. Sleep Health. 2020;6(5):618-622. doi:10.1016/j.sleh.2020.01.018
66. Sato-Mito N, Sasaki S, Murakami K, et al. The midpoint of sleep is associated with dietary intake and dietary behavior among young Japanese women. Sleep Med. 2011;12(3):289-294. doi:10.1016/j.sleep.2010.09.012
67. Średniawa A, Drwiła D, Krotos A, Wojtaś D, Kostecka N, Tomasik T. Insomnia and the level of stress among students in Krakow, Poland. Trends Psychiatry Psychother. 2019;41(1):60-68. doi:10.1590/2237-6089-2017-0154
68. Štefan L, Krističević T, Sporiš G. The associations of self-reported physical fitness and physical activity with sleep quality in young adults: A population-based study. Mental Health and Physical Activity 2018;14:131-5. doi:10.1016/j.mhpa.2018.04.002
69. Tran J, Lertmaharit S, Lohsoonthorn V, et al. Daytime Sleepiness, Circadian Preference, Caffeine Consumption and Use of Other Stimulants among Thai College Students. J Public Health Epidemiol. 2014;8(6):202-210. doi:10.5897/JPHE2014.0620
70. Trapp GS, Hurworth M, Jacoby P, et al. Energy drink intake is associated with insomnia and decreased daytime functioning in young adult females. Public Health Nutr. 2021;24(6):1328-1337. doi:10.1017/S1368980020001652
71. Vik P, Dorenkamp MA, Egusquiza JA, Miceli LB. Cannabis as a factor in the moderating relationship between alcohol, sleep, and adverse drinking consequences. Journal of Substance Use. 2019;12;25(1):76-81. doi:10.1080/14659891.2019.1664657
72. Vo K, Neafsey PJ, Lin CA. Concurrent use of amphetamine stimulants and antidepressants by undergraduate students. Patient Prefer Adherence. 2015;9:161-172. Published 2015 Jan 22. doi:10.2147/PPA.S74602
73. Vollmer-Conna U, Beilharz JE, Cvejic E, et al. The well-being of medical students: A biopsychosocial approach. Aust N Z J Psychiatry. 2020;54(10):997-1006. doi:10.1177/0004867420924086
74. Young DR, Sidell MA, Grandner MA, Koebnick C, Troxel W. Dietary behaviors and poor sleep quality among young adult women: watch that sugary caffeine!. Sleep Health. 2020;6(2):214-219. doi:10.1016/j.sleh.2019.12.006
75. Caviness CM, Anderson BJ, Stein MD. Impact of Nicotine and Other Stimulants on Sleep in Young Adults. J Addict Med. 2019;13(3):209-214. doi:10.1097/ADM.00000000000000481
76. DeMartini KS, Fucito LM. Variations in sleep characteristics and sleep-related impairment in at-risk college drinkers: a latent profile analysis. Health Psychol. 2014;33(10):1164-1173. doi:10.1037/hea0000115
77. Dugas EN, Sylvestre MP, O'Loughlin EK, et al. Nicotine dependence and sleep quality in young adults. Addict Behav. 2017;65:154-160. doi:10.1016/j.addbeh.2016.10.020
78. Miller MB, Boness CL, DiBello AM, Froeliger B. Insomnia as a moderator of alcohol use and blackout: Potential role in acute physiological consequences [published online ahead of print, 2022 Jun 7]. Addict Behav. 2022;134:107395. doi:10.1016/j.addbeh.2022.107395
79. Miller MB, Van Reen E, Barker DH, et al. The impact of sleep and psychiatric symptoms on alcohol consequences among young adults. Addict Behav. 2017;66:138-144. doi:10.1016/j.addbeh.2016.11.023
80. Cohen A, Colodner R, Masalha R, Haimov I. The Relationship Between Tobacco Smoking, Cortisol Secretion, and Sleep Continuity. Subst Use Misuse. 2019;54(10):1705-1714. doi:10.1080/10826084.2019.1608250
81. Cohen A, Ben Abu N, Haimov I. The Interplay Between Tobacco Dependence and Sleep Quality Among Young Adults. Behav Sleep Med. 2020;18(2):163-176. doi:10.1080/15402002.2018.1546707
82. Conroy DA, Kurth ME, Strong DR, Brower KJ, Stein MD. Marijuana use patterns and sleep among community-based young adults. $J$ Addict Dis. 2016;35(2):135-143.
doi:10.1080/10550887.2015.1132986
83. Rusnac N, Spitzenstetter F, Tassi P. Chronic sleep loss and risk-taking behavior: Does the origin of sleep loss matter?. Behav Sleep Med. 2019;17(6):729-739. doi:10.1080/15402002.2018.1483368
84. Hasler BP, Graves JL, Wallace ML, et al. Self-reported sleep and circadian characteristics predict alcohol and cannabis use: A longitudinal analysis of the National Consortium on Alcohol and Neurodevelopment in Adolescence Study. Alcohol Clin Exp Res. 2022;46(5):848860. doi:10.1111/acer. 14808
85. Liu S, Bamberger P, Wang M, Nahum-Shani I, Larimer M, Bacharach SB. Behavior change versus stability during the college-to-work transition: Life course and the "stickiness" of alcohol misuse at career entry. Personnel Psychology. 2022.doi:10.1111/peps. 12519
86. Samek DR, Akua BA. Predictors of persistent alcohol use disorder and co-occurring depressive symptoms: Insights from the longitudinal college experiences study. $J$ Adolesc. 2022;94(6):844-854. doi:10.1002/jad. 12068
87. Van Reen E, Roane BM, Barker DH, McGeary JE, Borsari B, Carskadon MA. Current Alcohol Use is Associated with Sleep Patterns in First-Year College Students. Sleep. 2016;39(6):1321-1326. Published 2016 Jun 1. doi:10.5665/sleep. 5862
88. Goodhines PA, Gellis LA, Ansell EB, Park A. Cannabis and alcohol use for sleep aid: A daily diary investigation. Health Psychol. 2019;38(11):1036-1047. doi:10.1037/hea0000765
89. Goodhines PA, Gellis LA, Kim J, Fucito LM, Park A. Self-Medication for Sleep in College Students: Concurrent and Prospective Associations With Sleep and Alcohol Behavior. Behav Sleep Med. 2019;17(3):327-341. doi:10.1080/15402002.2017.1357119
90. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4
91. Ebrahim IO, Shapiro CM, Williams AJ, Fenwick PB. Alcohol and sleep I: effects on normal sleep. Alcohol Clin Exp Res. 2013;37(4):539-549. doi:10.1111/acer. 12006
92. Heckman MA, Sherry K, De Mejia EG. Energy Drinks: An Assessment of Their Market Size, Consumer Demographics, Ingredient Profile, Functionality, and Regulations in the United States. Compr Rev Food Sci Food Saf. 2010;9(3):303-317. doi:10.1111/j.15414337.2010.00111.x
93. Fabbri M, Beracci A, Martoni M, Meneo D, Tonetti L, Natale V. Measuring Subjective Sleep Quality: A Review. Int J Environ Res Public Health. 2021;18(3):1082. Published 2021 Jan 26. doi:10.3390/ijerph18031082
94. Drazdowski TK, Kliewer WL, Marzell M. College students' using marijuana to sleep relates to frequency, problematic use, and sleep problems. J Am Coll Health. 2021;69(1):103-112. doi:10.1080/07448481.2019.1656634
95. Graupensperger S, Hultgren BA, Fairlie AM, Lee CM, Larimer ME. Using Alcohol and Cannabis as Sleep Aids: Associations with Descriptive Norms Among College Students. Behav Sleep Med. 2023;21(1):84-96. doi:10.1080/15402002.2022.2040505
96. Humphries RK, Bath DM, Burton NW. Dysfunctional beliefs, sleep hygiene and sleep quality in university students. Health Promot J Austr. 2022;33(1):162-169. doi:10.1002/hpja. 471
97. Voinescu BI, Szentagotai-Tatar A. Sleep hygiene awareness: its relation to sleep quality and diurnal preference. J Mol Psychiatry. 2015;3(1):1. Published 2015 Jan 31.
doi:10.1186/s40303-015-0008-2
98. Gellis LA, Park A, Stotsky MT, Taylor DJ. Associations between sleep hygiene and insomnia severity in college students: cross-sectional and prospective analyses. Behav Ther. 2014;45(6):806-816. doi:10.1016/j.beth.2014.05.002
99. Arnett, J. J., Žukauskienė, R., \& Sugimura, K. (2014). The new life stage of emerging adulthood at ages 18-29 years: implications for mental health. The lancet. Psychiatry, 1(7), 569576. https://doi.org/10.1016/S2215-0366(14)00080-7


Figure 1. A multidimensional framework. The association between different sleep dimensions and different substances is investigated. In the framework, we considered sleep disturbances, Buysse's sleep health dimensions, and circadian characteristics (left side) in their association with the use of alcohol, caffeine, nicotine, cannabis, and other substances (right side). The group "other substances" includes illicit substances (such as cocaine, amphetamines, heroine) and controlled drugs (such as tranquillizers, stimulants, opioids) (see Supplementary Table S1 for a complete list). Figure created with BioRender.com.


Figure 2. Flow chart of the study selection process. PRISMA 2020 flow diagram including searches of databases, registers, and other sources.


Figure 3. Literature organisation. Included studies ( $\mathrm{n}=46$ ) are organised based on study design and samples.
(a) Sleep disturbance and alcohol use

(b) Sleep disturbance and caffeine use

(c) Sleep disturbance and nicotine use


Figure 4. Forest plots. Random effect meta-analytic models: pooled odds ratios (ORs) of sleep disturbances for those consuming alcohol (a), caffeine (b), and nicotine (c), compared to nonconsumers. The right arm of the forest plot favours those reporting consumption of the substance compared to those reporting no consumption.

(b) Sleep duration and caffeine use

(c) Sleep duration and nicotine use


Figure 5. Forest plots. Random effect meta-analytic models: pooled odds ratios (ORs) of short sleep duration for those consuming alcohol (a), caffeine (b), and nicotine (c), compared to nonconsumers. The right arm of the forest plot favours those reporting consumption of the substance compared to those reporting no consumption.

Table 1. Descriptive characteristics of included studies by study design and sampling.

| Cross-sectional studies ( $\mathrm{n}=36$ ) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Unselected samples |  |  |  |  |  |  |  |  |  |  |
| Study | Country | Populatio n | Age range | Mean age (SD) | Sample size | Female (\%) | Substance | Sleep dimension | Sleep assessment | Risk of bias |
| $\begin{aligned} & \text { Adan } 1994 \\ & {[44]} \end{aligned}$ | Spain | G (31.8\% <br> C) | 21-30 | 25.3 (2.87) | 537 | 52.1 | Alcohol, caffeine (coffee) nicotine | Chronotype | rMEQ | High |
| Al Otaibi \& Kamel 2017 [45] | Saudi <br> Arabia | C | 18-26 | $\begin{aligned} & \text { F: } 21.1 \\ & \text { (2.2) M: } \\ & 22.8(6.1) \end{aligned}$ | 414 | 52.9 | Caffeine (energy drinks) | Sleep duration | Single item | Low |
| Al Sharif et al. 2018 [46] | Saudi Arabia | C | 18-25 | nr | 476 | 82.8 | Caffeine (coffee, energy drinks) | Sleep disturbances | PSQI | High |
| Arbinaga et al. 2019 [47] | Spain | C | 19-26 | 22.38 (2.13) | 444 | 56.1 | Nicotine | Sleep disturbances, sleep duration, sleep efficiency, sleep satisfaction, daytime dysfunction | PSQI | Low |
| Barbosa et al. $2020 \text { [48] }$ | Brazil | G | 18-19 | nr | 2514 | 52.4 | Caffeine (energy drinks) | Daytime dysfunction | ESS | Low |
| Bin <br> Ismayatim et al. 2021 [49] | Malaysia | C | 18-29 | $n \mathrm{r}$ | 256 | 59.8 | Nicotine | Sleep disturbances | PSQI, ISI | High |
| Bodur et al. $2021 \text { [50] }$ | Turkey | C | 19-24 | 21.4 (1.38) | 661 | 27.8 | Caffeine (coffee, energy drinks) | Chronotype | MEQ | Low |
| $\begin{aligned} & \text { Bogati et al. } \\ & 2020 \text { [51] } \end{aligned}$ | Nepal | C | 19-27 | 21.97 (1.37) | 350 | 42.6 | Alcohol, caffeine (coffee, energy drinks), nicotine | Sleep disturbances, sleep duration, sleep efficiency, daytime dysfunction | PSQI | High |
| Elwasify et al. 2016 [52] | Egypt | C | 18-24 | 21.4 | 1182 | 67.7 | Caffeine, nicotine | Sleep disturbances | PSQI | Low |


| Hug et al. $2019 \text { [53] }$ | Switzerlan d | G | 18-25 | 21.7 (1.7) | 146 | 100 | Alcohol, caffeine (coffee, energy drinks) | Sleep timing | MCTQ | Low |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Kianersi et al. $2021 \text { [54] }$ | USA | G (30.5\% <br> C) | 18-24 | nr | 19701 | 45.3 | Alcohol, nicotine | Sleep duration | Single item | Low |
| Liao et al. $2019 *[55]$ | China | G | 18-29 | nr | 6124 | nr | Nicotine | Sleep disturbances | PSQI | Low |
| Liu et al. $2021 \text { [56] }$ | USA | C | 18-24 | 20.05 (1.75) | 820 | 62.7 | Alcohol, other substances | Sleep disturbances | PSQI | Low |
| Lohsoonthor n et al. 2013 [57] | Thailand | C | 18-28 | 20.3 (1.3) | 2854 | 67.4 | Alcohol, caffeine (coffee, energy drinks), nicotine | Sleep disturbances, sleep duration, sleep efficiency, daytime dysfunction | PSQI | Low |
| Mendoza et <br> al. 2021 [58] | Peru | C | 19-22 | nr | 289 | 66.1 | Caffeine (coffee, energy drinks) | Sleep disturbances | ISI | High |
| Naito et al. $2021 \text { [59] }$ | Malaysia | C | 18-25 | 20.71 (1.47) | 1017 | 51 | Alcohol, nicotine | Sleep duration | Single item | Low |
| Nakade et al. 2009 [60] | Japan | C | 18-29 | 19.26 (1.33) | 800 | 100 | Alcohol, nicotine | Chronotype | rMEQ | High |
| Ogilvie et al. <br> 2018 [61] | USA | G | 20-30 | nr | 1854 | 55.6 | Caffeine (coffee, energy drinks) | Sleep duration, sleep timing | Authorconstructed questionnaire | Low |
| Orsal et al. $2012 \text { [62] }$ | Turkey | C | 18-27 | 21.3 (1.91) | 803 | 55.2 | Alcohol, nicotine | Sleep disturbances | PSQI | High |
| Pham et al. $2021 \text { [63] }$ | Vietnam | C | 18-25 | 20.3 (2.5) | 369 | 65.6 | Alcohol, caffeine (coffee, energy drinks), nicotine | Sleep disturbances | PSQI | High |


| Riera-Sampol et al. 2022** [64] | Spain | C | 18-25 | 20.6 (2.1) | 886 | 68.6 | Alcohol, caffeine (coffee, energy drinks), cannabis, nicotine | Sleep disturbances | MOS-SS | Low |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Rosso et al. } \\ & 2020^{* *}[65] \end{aligned}$ | USA | C | 18-25 | 20.9 (1.5) | 4376 | 59.3 | Alcohol, nicotine | Sleep satisfaction | Single item | Low |
| Sato-Mito et <br> al. 2011 [66] | Japan | C | 18-20 | 18.1 (0.3) | 3304 | 100 | Nicotine | Sleep timing | MTCQ | High |
| Średniawa et al. 2019 [67] | Poland | C | 18-26 | 22.22 (1.5) | 264 | 56.8 | Nicotine | Sleep disturbances | AIS | High |
| Štefan et al. $2018 \text { [68] }$ | Croatia | C | 18-24 | 20.87 (2.11) | 2100 | 50.4 | Alcohol, nicotine | Sleep disturbances | PSQI | Low |
| $\begin{aligned} & \text { Tran et al. } \\ & 2014 \text { [69] } \end{aligned}$ | Thailand | C | 18-28 | 20.3 (1.3) | 3000 | 66.9 | Alcohol, caffeine (coffee, energy drinks), nicotine | Chronotype, daytime dysfunction | MEQ, ESS | Low |
| Trapp et al. 2021 [70] | Australia | G | 22 | nr | 1115 | 53.7 | Caffeine (energy drinks) | Sleep disturbances, daytime dysfunction | PSSQ-I, ESS | Low |
| Vik et al. $2020 * *[71]$ | USA | (C) | 18-20 | nr | 144 | 58.7 | Alcohol | Sleep disturbances | PSQI | Low |
| Vo et al. 2015 [72] | USA | C | 18-24 | 20 | 1976 | 70.4 | Prescription drugs | Sleep duration | Single item | Low |
| VollmerConna et al. $2020 * *[73]$ | Australia | C | 20-27 | 21.8 (1.05) | 151 | 60.3 | Caffeine | Sleep disturbances | PSQI | Low |
| $\begin{aligned} & \text { Young et al. } \\ & 2020 \text { [74] } \end{aligned}$ | USA | G | 22-23 | 22.9 (0.45) | 462 | 100 | Caffeine (energy drinks) | Sleep disturbances, sleep duration, sleep efficiency, sleep satisfaction, daytime dysfunction | PSQI | Low |


| Selected samples reporting substance use |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Study | Country | Substance use reported | Age range | Mean age (SD) | Sample size | $\begin{aligned} & \text { Female } \\ & (\%) \end{aligned}$ | Substances | Sleep dimension | Sleep assessment | Risk of bias |
| Caviness et al. 2019 [75] | USA | Cannabis or alcohol ( $60.4 \% \mathrm{C}$ ) | 18-25 | 21.3 (2.07) | 498 | 52.2 | Alcohol, caffeine (coffee, energy drinks), cannabis, nicotine, prescription medications | Sleep duration, sleep efficiency, sleep satisfaction | PSQI | Low |
|  <br> Fucito 2014 <br> [76] | USA | Alcohol (C) | 18-25 | 18.90 (0.97) | 312 | 43.3 | Alcohol | Sleep timing | SWPS | Low |
| Dugas et al. $2017 \text { [77] }$ | USA | Nicotine | 22-26 | 24 (0.6) | 405 | 55.1 | Nicotine | Sleep disturbances | PSQI | Low |
| Miller et al. 2022 [78] | USA | Alcohol (C) | 18-30 | 19.0 (1.4) | 461 | 68.8 | Alcohol, other substances | Insomnia | ISI | Low |
| Miller, Van <br> Reen et al. <br> 2017 [79] | USA | Alcohol <br> (C) | 18-30 | 18.6 (0.4) | 385 | 51.7 | Alcohol | Sleep disturbances | PSQI | Low |


| Case-Control studies ( $\mathrm{n}=4$ ) |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Study | Country | Case definition | Age range | Mean age (SD) | Sample size | Female (\%) | Substance | Sleep dimension | Sleep assessment | Risk of bias |
| Cohen et al. 2019 [80] | Israel | Current smokers <br> (C) | 19-30 | $\begin{aligned} & \text { Case; } 23.92 \\ & \text { (2.94); } \\ & \text { Control: } \\ & 23.05(1.82) \end{aligned}$ | 77 | 74 | Nicotine | Sleep disturbances | PSQI | Low |


| Cohen et al. $2020 \text { [81] }$ | Israel | Current smokers (C) | 19-28 | Case: 24.03 <br> (2.84); <br> Control: $22.44(2.23)$ | 86 | 69.8 | Nicotine | Sleep disturbances, sleep duration, sleep efficiency, sleep satisfaction, daytime dysfunction | PSQI | Low |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Conroy et al. $2016 \text { [82] }$ | USA | Habitual and occasional cannabis users (G) | 18-29 | 22.3 (3.0) | 98 | 54.1 | Cannabis | Sleep disturbances, daytime dysfunction chronotype | PSQI, ISI, <br> ESS, MEQ | Low |
| Rusnac et al. $2018 \text { [83] }$ | USA | Sleep deprivation and insomnia (C) | 19-25 | nr | 536 | 47 | Alcohol | Sleep disturbances, sleep duration | ISI, single item | High |
| Prospective studies ( $\mathrm{n}=\mathbf{6}$ ) |  |  |  |  |  |  |  |  |  |  |
| Unselected samples |  |  |  |  |  |  |  |  |  |  |
| Study | Country | Populatio n | Baseline age range and time points | Baseline mean age (SD) | Baseline sample size | $\begin{aligned} & \text { Female } \\ & \text { (\%) } \end{aligned}$ | Substance and time point of assessment | Sleep dimension and time point of assessment | Sleep assessment | Risk of bias |
| Hasler et al. 2022*** [84] | USA | G | 18-21 | 19.6 (1.1) | 637 | 53.8 | Alcohol, cannabis | Sleep duration, sleep satisfaction, sleep timing, daytime dysfunction, chronotype | $\begin{aligned} & \hline \text { CASQ, PSQI, } \\ & \text { STQ, CSM } \end{aligned}$ | Low |
| Liu et al. 2022 [85] | USA | C | 19-25 | 21.36 (0.81) | 1363 | 61 | Alcohol | Sleep satisfaction | Single item | High |
|  <br> Akua 2022** <br> [86] | USA | C | 18-20 | 19.1 (0.41) | 209 | 61.7 | Alcohol, cannabis | Sleep duration | Two items | Low |
| Van Reen et al. 2016 [87] | USA | C | 18-22 | nr | 878 | 50.1 | Alcohol | Sleep duration, sleep timing, sleep variability | Sleep diary | High |


| Study | Country | Substance <br> use reported | Baseline age range | Baseline mean age (SD) | Sample <br> size | Female $(\%)$ | Substance | Sleep dimension | Sleep assessment | Risk of bias |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Goodhines, Gellis, Ansell, \& Park 2019 [88] | USA | Alcohol, cannabis (C) | 18-25 | 19.33 (1.11) | 217 | 76 | Alcohol, cannabis (sleep aid) | Sleep disturbances, sleep duration, sleep satisfaction, daytime dysfunction | PSQI, sleep diary (CSD) | Low |
| Goodhines, Gellis, Kim et al. 2019 | USA | Alcohol, cannabis (C) | 18-28 | 19 (1.32) | 171 | 67.8 | Alcohol, cannabis, OTC | Sleep disturbances, sleep duration, chronotype | ISI, single item, MEQ | Low |

## Notes

Abbreviations: C: College students only; G: College and non-college students recruited (percentage in parenthesis represents number of college students in the sample, when reported;); nr: Not reported; F: Females; M: Males;
Questionnaires: AIS: Athens Insomnia Scale; ESS: Epworth Sleepiness Scale; CASQ: Cleveland Adolescent Sleepiness Questionnaire; CSD: Consensus Sleep Diary; CSM: Composite Scale of Morningness; ISI: Insomnia Severity Index; MCTQ: Munich Chronotype Questionnaire; MEQ: Morningness-Eveningness Questionnaire; MOS-SS: Medical Outcome Study-Sleep Scale; PSQI: Pittsburgh Sleep Quality Index; PSSQ-I: Pittsburgh Sleep Symptoms Questionnaire- Insomnia; rMEQ: Morningness-Eveningness Questionnaire-reduced; STQ: Sleep Timing Questionnaire; SWPS: Sleep/Wake Behavior Problems Scale.
All caffeine refers to caffeinated drinks; in parentheses the drinks included in this category are indicated for each study; when only caffeine is reported, it indicates that the specific substance was not reported.
Cut-off for risk of bias judgment is 15 on the AXIS for cross-sectional studies and 5 on the NOS for case-control and prospective studies.
*Age subgroup of a larger sample ( $\mathrm{n}=26035$ ) aged 12 to $60+$ years
**Studies included after the corresponding authors had provided requested data via personal communication
***Age subgroup of a larger accelerated longitudinal design (age range 12-27)

Table 2. Characteristics and main findings of studies on sleep disturbances, divided by study design and sample.

## Sleep disturbances ( $\mathrm{n}=24$ )

| Reference | Type of sample (n) | Sleep assessment | Substance (Use\%) | Substance assessment | Main findings on sleep disturbances |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Al Sharif et al. 2018 [46] | $\begin{aligned} & \hline \mathrm{C} \\ & (\mathrm{n}=476) \end{aligned}$ | PSQI | $\begin{aligned} & \hline \text { Coffee } \\ & (92 \%) \end{aligned}$ | Level of consumption in cups per day: tolerable ( $1-3$ cups), excessive (at least 4 cups) | Sleep disturbances: higher prevalence of excessive use |
| Arbinaga et al. 2019 [47] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=444) \end{aligned}$ | PSQI | Nicotine (41.2\%) | Current use | Use vs non-use: higher odds of sleep disturbances; higher PSQI scores |
| Bin Ismayatim et al. 2021 [49] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=256) \end{aligned}$ | PSQI; ISI | $\begin{aligned} & \text { Nicotine } \\ & (10.2 \%) \end{aligned}$ | Current use | Use vs non-use: higher prevalence of sleep disturbances |
| Bogati et al.$2020 \text { [51] }$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=350) \end{aligned}$ | PSQI | Alcohol (38\%) | Level of consumption in units per month: low ( $0-4$ units), moderate (4-15 units), high (>16 units) | Use vs non-use: higher odds of sleep disturbances |
|  |  |  | $\begin{aligned} & \text { Coffee } \\ & (96 \%) \end{aligned}$ | Level of consumption in mg per day: low ( $<100 \mathrm{mg}$ ), moderate ( $100-250 \mathrm{mg}$ ), high ( $>250 \mathrm{mg}$ ) | Use vs non-use: higher odds of sleep disturbances |
|  |  |  | $\begin{aligned} & \text { Nicotine } \\ & (14.3 \%) \end{aligned}$ | Level of consumption in cigarettes per week: low ( $<10$ cigarettes), moderatehigh ( $\geq 10$ cigarettes) | Use vs non-use: higher odds of sleep disturbances |
| Elwasify et al. 2016 [52] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=1182) \end{aligned}$ | PSQI | $\begin{aligned} & \text { Caffeine } \\ & \text { (85.5\%) } \end{aligned}$ | Daily use | Use vs non-use: higher odds of sleep disturbances |
|  |  |  | Nicotine (3.4\%) | Current use | Use vs non-use: higher odds of sleep disturbances |
| Liao et al. 2019 [55] | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=7590) \end{aligned}$ | PSQI | $\begin{aligned} & \text { Nicotine } \\ & (21.9 \%) \end{aligned}$ | Current use | Use vs non-use: higher prevalence of sleep disturbances |
| $\begin{aligned} & \text { Liu et al. 2021* } \\ & {[56]} \end{aligned}$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=746) \end{aligned}$ | PSQI | Alcohol (nr) | Frequency of use, frequency of heavy episodic drinking | Sleep disturbances: higher frequency of use |
|  |  |  | Other substances (nr) | Current use | Sleep disturbances: higher number of substances used |


| Lohsoonthorn et al. 2013 [57] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=2854) \end{aligned}$ | PSQI | Alcohol (34.2\%) | Level of consumption in drinks per week: low ( $<1$ drink), moderate (1-19 drinks), high ( $\geq 20$ drinks) | Use vs non-use: higher odds of sleep disturbances |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | $\begin{aligned} & \text { Caffeine } \\ & (58 \%) \end{aligned}$ | Use defined as at least one stimulant drink per week | Use vs non-use: higher odds of sleep disturbances |
|  |  |  | $\begin{aligned} & \text { Nicotine } \\ & (6.8 \%) \end{aligned}$ | Current use | No association |
| Mendoza et al.$2021 \text { [58] }$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=289) \end{aligned}$ | ISI | $\begin{aligned} & \text { Coffee } \\ & (81.3 \%) \end{aligned}$ | Current use | No association |
|  |  |  | Energy drinks (39.4\%) | Number of drinks/month; number of days of use/month; number of drinks per sitting | Higher frequency and greater quantity of use: higher prevalence of sleep disturbances |
| Orsal et al.$2012 \text { [62] }$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=803) \end{aligned}$ | PSQI | Alcohol (30.5\%) | Current use | Use vs non-use: higher odds of sleep disturbances |
|  |  |  | Nicotine $(35 \%)$ | Current use | No association |
| Pham et al.$2021 \text { [63] }$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=369) \end{aligned}$ | PSQI | Alcohol (36\%) | Use after 4 pm | Use vs non-use: higher PSQI scores |
|  |  |  | Coffee (15.4\%) | Use after 4 pm | Use vs non-use: higher PSQI scores |
|  |  |  | Energy drinks (10.3\%) | Use after 4 pm | No association |
|  |  |  | Nicotine (4.3\%) | Current use | No association |
| Riera-Sampol et al. 2022* [64] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=886) \end{aligned}$ | MOS-SS | Alcohol (78.5\%) | Frequency of use | Use vs non-use: higher MOS-SS scores |
|  |  |  | $\begin{aligned} & \text { Caffeine } \\ & (93.2 \%) \end{aligned}$ | $\mathrm{Mg} /$ day caffeinated drinks; use of coffee, use of energy drinks | Use vs non-use: higher MOS-SS scores |


|  |  |  | $\begin{aligned} & \text { Cannabis } \\ & (4.5 \%) \end{aligned}$ | Current use | No association |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | $\begin{aligned} & \text { Nicotine } \\ & (18.5 \%) \end{aligned}$ | Current use | No association |
| Średniawa et al. 2019 [67] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=264) \end{aligned}$ |  | AIS | Nicotine (17\%) | Current use | Use vs non-use: higher prevalence of sleep disturbances |
| Štefan et al.$2018 \text { [68] }$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=2100) \end{aligned}$ | PSQI | Alcohol (27.1\%) | At least one heavy episodic drinking | No association |
|  |  |  | Nicotine (24.1\%) | Current use | Use vs non-use: higher odds of sleep disturbances |
| Trapp et al. $2021 \text { [70] }$ | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=934) \end{aligned}$ | PSSQ-I | Energy drinks $(35.3 \%)$ | Use at least once/week | Use vs non-use: higher odds of sleep disturbances; higher PSSQ-I scores (in F) |
| Vik et al. $2020 *[71]$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=144) \end{aligned}$ | PSQI | Alcohol (49.3\%) | Use at least once/past 3 months | No association |
| Vollmer-Conna et al. 2020* <br> [73] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=148) \end{aligned}$ | PSQI | Coffee <br> (nr) | Cups/day | Sleep disturbances: lower consumption |
| Young et al. 2020 [74] | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=462) \end{aligned}$ | PSQI | Energy drinks (12.1\%) | Number of drinks/day | Use vs non-use: higher prevalence of sleep disturbances; higher PSQI scores |

## Cross-sectional studies on selected samples ( $n=3$ )

| Dugas et al. | Nicotine use in <br> past year $(G)$ <br> $(\mathrm{n}=405)$ | PSQI | Nicotine | Frequency/past year, number of <br> cigarettes smoked/past month | Higher number of cigarettes smoked in past month: higher odds of <br> reporting a sleep disturbance |
| :--- | :--- | :--- | :--- | :--- | :--- |
|  |  |  |  |  |  |


| Miller et al. 2022 [78] | Heavy drinking in the past 30 days (C) ( $\mathrm{n}=461$ ) |  | Alcohol | Drinking days/week, drinks/drinking day, days of binge drinking/week, days $12+$ drinks/sitting, maximum drinking quantity | Sleep disturbances: higher frequency of 12+ drinks/sitting |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Other substances | Any use in past month | Sleep disturbance: higher prevalence of consumption |
| Miller, Van Reen et al. 2017 [79] | Violation of campus alcohol policy (C) ( $\mathrm{n}=385$ ) | PSQI | Alcohol | Number of heavy drinking days (diary) | No association |
|  |  |  |  | Case-control studies ( $n=3$ ) |  |
| Cohen et al. $2019 \text { [80] }$ | Current smokers vs. non-smokers (C) ( $\mathrm{n}=38$ cases; n $=39$ controls) | PSQI | Nicotine | Case definition: at least 10 cigarettes a day for at least 2 years in the smokers' group | No significant difference between smokers and non-smokers |
| Cohen et al. $2020 \text { [81] }$ | Current smokers vs. non-smokers (C) ( $\mathrm{n}=40$ cases; n = 46 controls) | PSQI | Nicotine | Case definition: at least 10 cigarettes a day for at least 2 years in the smokers' group | No significant difference between smokers and non-smokers |

Conroy et al. \begin{tabular}{l}
Habitual and <br>
occasional <br>
cannabis users <br>
vs. non-users

$\quad$ PSQI, ISI Cannabis $\quad$

Case definition: use in past month (daily <br>
and non-daily)

 

Higher prevalence of sleep disturbances in daily consumers <br>
compared to non-daily consumers and to non-consumers (both PSQI <br>
and ISI)
\end{tabular}

[^0]Table 3. Characteristics and main findings of studies on each sleep health dimension, divided by study design and sample.

| Sleep health dimensions |
| :---: | :---: |
| Sleep duration (n=11) |


| Cross-sectional studies on unselected samples ( $n=9$ ) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Study | Type of sample ( n ) | Sleep assessment | $\begin{aligned} & \hline \begin{array}{l} \text { Substance } \\ \text { (Use\%) } \end{array} \end{aligned}$ | Substance assessment | Main findings on sleep duration |
| Al Otaibi \& Kamel 2017 [45] | $\mathrm{C}(\mathrm{n}=414)$ | Single item | Energy drinks (39.9\%) | Use defined as at least one drink/week | Use vs non-use: higher odds of short sleep duration; shorter average sleep duration |
| Arbinaga et al. 2019 [47] | $\mathrm{C}(\mathrm{n}=444)$ | PSQI | Nicotine (41.2\%) | Current use | Use vs non-use: not higher odds of short sleep duration; shorter average sleep duration |
| Bogati et al. 2020 [51] | $\mathrm{C}(\mathrm{n}=350)$ | PSQI | Alcohol (38.3\%) | Level of consumption in units per month: low ( $0-4$ units), moderate (415 units), high ( $>16$ units) | Use vs non-use: higher odds of short sleep duration |
|  |  |  | $\begin{aligned} & \text { Caffeine } \\ & (96 \%) \end{aligned}$ | Level of consumption in mg per day: low ( $<100 \mathrm{mg}$ ), moderate (100-250 mg ), high ( $>250 \mathrm{mg}$ ) | Use vs non-use: higher odds of short sleep duration; higher level of use: higher odds of short sleep duration |
|  |  |  | $\begin{aligned} & \text { Nicotine } \\ & (14.3 \%) \end{aligned}$ | Level of consumption in cigarettes per week: low ( $<10$ cigarettes), moderatehigh ( $\geq 10$ cigarettes) | Use vs non-use: higher odds of short sleep duration |
| Kianersi et al.$2021 \text { [54] }$ | $G(\mathrm{n}=18766)$ | Single item | Alcohol (53.3\%) | Use in last 30 days | Use vs non-use: higher prevalence of short sleep duration |
|  |  |  | Nicotine (12.3\%) | Occasional and frequent use | Use vs non-use: higher prevalence of short sleep duration |
| Lohsoonthorn et al. 2013 [57] | $\mathrm{C}(\mathrm{n}=284)$ | PSQI | Alcohol (23\%) | Level of consumption in drinks per week: low ( $<1$ drink), moderate (1-19 drinks), high ( $\geq 20$ drinks) | Moderate Use vs non-use: higher odds of long sleep duration |
|  |  |  | Caffeine (58\%) | Use defined as at least one stimulant drink per week | Use vs non-use: higher odds of short sleep duration |


|  |  |  | $\begin{aligned} & \text { Nicotine } \\ & (6.9 \%) \end{aligned}$ | Current use | Use vs non-use: higher odds of short sleep duration |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Naito et al.$2021 \text { [59] }$ | $\mathrm{C}(\mathrm{n}=1017)$ | Single item | Alcohol (19.5\%) | Current use | Use vs non-use: higher prevalence of long sleep duration |
|  |  |  | Nicotine (2.9\%) | Current use | No association |
| Ogilvie et al.$2018 \text { [61] }$ | $\mathrm{G}(\mathrm{n}=1773)$ | Authorconstructed questionnaire | Coffee (nr) | Drinks per day | No association |
|  |  |  | Energy drinks (17.9\%) | Current use | No association |
| Vo et al. 2015 [72] | $C(\mathrm{n}=1976)$ | Single item | Stimulant medications (4\%) | Current use | No association |
| Young et al. 2020 [74] | $\mathrm{G}(\mathrm{n}=462)$ | PSQI | Energy drinks <br> (12.1\%) | Use at least once a day | No association |
| Cross-sectional studies on selected samples ( $n=1$ ) |  |  |  |  |  |
| Caviness et <br> al. 2019 [75] | Cannabis or alcohol use in past month ( $60.4 \% \mathrm{C})(\mathrm{n}=498)$ | PSQI | Prescription stimulant medications used nonmedically (NPS), nicotine, caffeine, cocaine | Days of use in last 90 days for NPS, cigarettes per day in last 30 days for nicotine | Higher number of days of NPS use: higher odds of short sleep duration <br> No other association |
|  |  |  |  | Case-control studies ( $n=1$ ) |  |
| $\begin{aligned} & \hline \text { Rusnac et al. } \\ & 2018 \text { [83] } \end{aligned}$ | Sleep deprivation vs. sufficient sleep (C) | authorconstructed questionnaire | Alcohol | Frequency of consumption, number of drinks per week | Sleep loss sleep loss compared to sufficient sleep: higher quantity of alcohol consumed |

$$
\begin{aligned}
& (\mathrm{n}=134 \text { cases; } \mathrm{n}= \\
& 299 \text { controls })
\end{aligned}
$$

|  |  |  | Sleep satisfaction (n=4) |  |
| :--- | :--- | :--- | :--- | :--- |
|  |  |  | Cross-sectional studies on unselected samples $(\boldsymbol{n}=3)$ |  |
| Study | Population | Sleep <br> assessment | Substance <br> (Use\%) | Substance assessment |


| Caviness et <br> al. 2019 [75] | Cannabis or alcohol <br> use in past month <br> $(60.4 \%$ C $)$ <br> $(\mathrm{n}=498)$ | PSQI | Prescription <br> stimulant <br> medications <br> used non- <br> medically <br> (NPS), <br> nicotine, <br> caffeine, <br> cocaine | Days of use in past 90 days for NPS, <br> cigarettes/day in past 30 days for <br> nicotine | Higher number of cigarettes/day: higher odds of low sleep <br> satisfaction <br> No other association |
| :--- | :--- | :--- | :--- | :--- | :--- |


|  | Caffeine <br> $(58 \%)$ | Use defined as at least one stimulant <br> drink per week | Use vs non-use: higher odds of low sleep efficiency |  |
| :--- | :--- | :--- | :--- | :--- |
| Young et al. | G | PSQI | Nicotine <br> $(6.9 \%)$ | Current use |


| Cross-sectional studies on selected samples ( $n=1$ ) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Caviness et <br> al. 2019 [75] | Cannabis or alcohol use in past month $\begin{aligned} & (60.4 \% \mathrm{C}) \\ & (\mathrm{n}=498) \end{aligned}$ | PSQI | Prescription stimulant medications used nonmedically (NPS), nicotine, caffeine, cocaine | Days of use in past 90 days for NPS, cigarettes/day in past 30 days for nicotine | Higher number of cigarettes/day: higher odds of low sleep efficiency |
|  |  |  |  |  | No other association |


| Sleep timing ( $\mathrm{n}=4$ ) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Cross-sectional studies on unselected samples ( $n=3$ ) |  |  |  |  |  |
| Study | Population | Sleep assessment | Substance (Use\%) | Substance assessment | Main findings on sleep timing |
| $\begin{aligned} & \hline \text { Hug et al. } \\ & 2019 \text { [53] } \end{aligned}$ | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=146) \end{aligned}$ | MCTQ (midpoint of sleep) | Alcohol (nr) | Quantity in mL with diary | Latest midpoint: higher frequency of consumption |
|  |  |  | Coffee (nr) | Quantity in cups with diary | No association |


| Ogilvie et al. <br> $2018[61]$ | G <br> $(\mathrm{n}=1854)$ | Author- <br> constructed <br> questionnaire <br> (bedtime) | Caffeine <br> $(\mathrm{nr})$ | Quantity in drinks per day |
| :--- | :--- | :--- | :--- | :--- | | Latest bedtime: higher frequency of consumption <br> (adjusted means) |
| :--- |
| Sato-Mito et <br> al. 2011 $[66]$ C  <br> $(\mathrm{n}=3304)$ MCTQ <br> (midpoint of <br> sleep) Nicotine <br> $(1.3 \%)$ |


|  |  |  | Cross-sectional studies on selected samples ( $\boldsymbol{n}=\boldsymbol{1}$ ) |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| DeMartini \& | Excessive alcohol use | SWPS | Alcohol | Quantity in drinks in a typical week; | Those reporting sleepiness and late bedtime compared to |
| Fucito 2014 | defined by AUDIT-C | (bedtime) |  | frequency of heavy episodic drinking | sleepiness alone: higher level of alcohol consumption |
| $[76]$ | scores (C) |  |  |  |  |
|  | $(\mathrm{n}=312)$ |  |  |  |  |


|  |  |  | Daytime dysfunction ( $\mathrm{n}=\mathbf{8}$ ) |  |
| :--- | :--- | :--- | :--- | :--- |
|  |  |  | Cross-sectional studies on unselected samples ( $\boldsymbol{n}=7$ ) |  |$]$


| Barbosa et al. <br> 2020 [48] |  |  | Energy <br> drinks <br> $(24 \%)$ |
| :--- | :--- | :--- | :--- |
| Bogati et al. <br> 2020 [51] | C |  |  |
| $(\mathrm{n}=350)$ | PSQI | Alcohol <br> $(38.3 \%)$ |  |
|  |  |  | Coffee <br> $(96 \%)$ |
|  |  |  | Nicotine <br> $(14.3 \%)$ |
|  |  |  | PSQI |

Energy

Alcohol (38.3\%)
(96\%)

Nicotine (14.3\%)

Alcohol
$(23 \%)$

Caffeine

Nicotine
(6.9\%)

Alcohol
$(35.2 \%)$

Level of consumption in units per month: low (0-4 units), moderate (415 units), high ( $>16$ units)

Level of consumption in mg per day: low ( $<100 \mathrm{mg}$ ), moderate ( $100-250$ $\mathrm{mg})$, high ( $>250 \mathrm{mg}$ )

Level of consumption in cigarettes per No association week: low ( $<10$ cigarettes), moderatehigh ( $\geq 10$ cigarettes)

Level of consumption in drinks per week: low ( $<1$ drink), moderate (1-19 drinks), high ( $\geq 20$ drinks)

Use defined as at least one stimulant drink per week

Current use

Level of consumption in drinks per week: low ( $<1$ drink), moderate (1-19
drinks), high ( $\geq 20$ drinks)

Use defined as at least one stimulant drink per week

Use vs non-use: higher risk of excessive daytime sleepiness

Use vs non-use: higher odds of daytime dysfunction Use vs non-use: higher odds of daytime dysfunction Q (

Use vs non-use: higher odds of daytime dysfunction

Use vs non-use: higher odds of daytime dysfunction

Use vs non-use: higher odds of daytime dysfunction (adjusting for covariates)

Use vs non-use: higher ESS scores

Use vs non-use: higher odds of excessive daytime sleepiness; no association with coffee

|  |  | Nicotine <br> $(7 \%)$ | Current use | No association |
| :--- | :--- | :--- | :--- | :--- |
| Trapp et al. <br> $2021[70]$ | G <br> $(\mathrm{n}=937)$ | ESS | Energy <br> drinks <br> $(35.4 \%)$ | Use defined as at least once a week |$\quad$| Use vs non-use: higher odds of excessive daytime |
| :--- |
| sleepiness; higher ESS scores (in F) |

## Case-control studies ( $n=1$ )

| Case-control studies ( $n=1$ ) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \hline \text { Conroy et al. } \\ & 2016 \text { [82] } \end{aligned}$ | Habitual and occasional cannabis users vs. non-users (G) ( $\mathrm{n}=78$ cases; $\mathrm{n}=20$ controls) | PSQI, ISI | Cannabis | Use in past month: daily and non-daily | No significant difference between consumers and nonconsumers |

## Notes:

Abbreviations: C: College students only; G: College and non-college students recruited; nr: Not reported; F: Females
Questionnaires: AIS: Athens Insomnia Scale; ESS: Epworth Sleepiness Scale; CASQ: Cleveland Adolescent Sleepiness Questionnaire; CSD: Consensus Sleep Diary; CSM: Composite Scale of Morningness; ISI: Insomnia Severity Index; MCTQ: Munich Chronotype Questionnaire; MEQ: Morningness-Eveningness Questionnaire; MOS-SS: Medical Outcome Study-Sleep Scale; PSQI: Pittsburgh Sleep Quality Index; PSSQ-I: Pittsburgh Sleep Symptoms Questionnaire- Insomnia; STQ: Sleep Timing Questionnaire; SWPS: Sleep/Wake Behavior Problems Scale.

Table 4. Characteristics and main findings of studies regarding chronotype, divided by study design.

| Chronotype ( $\mathrm{n}=5$ ) |
| :---: |
| Cross-sectional studies on unselected samples ( $\mathrm{n}=4$ ) |


| Study | Population | Sleep assessment | Substance (Use\%) | Substance assessment | Main findings on chronotype |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Adan } 1994 \\ & {[44]} \end{aligned}$ | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=573) \end{aligned}$ | rMEQ | Alcohol (nr) | Quantity in mL/day | Eveningness: higher daily consumption |
|  |  |  | Coffee (nr) | Quantity in mg/day | Eveningness: higher daily consumption |
|  |  |  | Nicotine (nr) | Quantity in cigarettes/day | Eveningness: higher daily consumption |
| Bodur et al. <br> 2021 [50] <br> Nakade et al. <br> 2009 [60] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=661) \\ & \mathrm{C} \\ & (\mathrm{n}=800) \end{aligned}$ | MEQ | Caffeine (nr) | Quantity in mg/day | Eveningness: higher levels of consumption |
|  |  | rMEQ | Alcohol (21.5\%) | Current use | Use vs non-use: lower MEQ scores* |
|  |  |  | Nicotine (8.3\%) | Current use | Use vs non-use: lower MEQ scores* |
| $\begin{aligned} & \text { Tran et al. } \\ & 2014 \text { [69] } \end{aligned}$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=2906) \end{aligned}$ | MEQ | Alcohol (35.2\%) | Level of consumption in drinks per week: low ( $<1$ drink), moderate (119 drinks), high ( $\geq 20$ drinks) | Use vs non-use: lower MEQ scores* |
|  |  |  | Caffeine (57.4\%) | Use defined as at least one stimulant drink per week | Use vs non-use: higher odds of being an evening chronotype |
|  |  |  | Nicotine (7\%) | Current use | Use vs non-use: lower MEQ scores* |


| Case-control studies ( $n=1$ ) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \hline \text { Conroy et al. } \\ & 2016 \text { [82] } \end{aligned}$ | Cannabis users vs. non-users (G) ( $\mathrm{n}=78$ cases; n = 20 controls) | MEQ | Cannabis | Use in past month: daily and nondaily | No significant difference between consumers and nonconsumers |

[^1]Table 5. Details and main findings of prospective studies on unselected (a) and selected (b) samples.

| Prospective studies |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (a) Unselected population ( $n=4$ ) |  |  |  |  |  |  |  |
| Study | Population | Follow-up | Substance | Substance assessment | Sleep assessment | Sleep variables | Main findings on sleep disturbance, sleep health, chronotype |
| Hasler et al., 2022 [84] | $\begin{aligned} & \mathrm{G} \\ & (\mathrm{n}=637) \end{aligned}$ | 6 years | Alcohol, cannabis | Frequency, quantity, heavy episodic drinking | $\begin{aligned} & \hline \text { CSM, CASQ, } \\ & \text { PSQI, STQ } \end{aligned}$ | Sleep duration, sleep satisfaction, sleep timing, daytime dysfunction, chronotype | Eveningness and late timing > more severe binge category the subsequent year; no association for cannabis use |


| $\begin{aligned} & \text { Liu et al. } \\ & 2022 \text { [85] } \end{aligned}$ | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=1363) \end{aligned}$ | 3: last semester of college, first full-time employment (M=8.34 months, SD: 2.80), 12 months after employment | Alcohol | Drinks in a typical week/past month | Single item | Sleep satisfaction | Staying in the high-risk drinking profile $>$ more sleep problems compared to those reducing to moderate drinking profile |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  <br> Akua 2022* <br> [86] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=167) \end{aligned}$ | 3: first year of college, 1 year later, 4 year later | Alcohol, cannabis | Frequency/past month | Single item | Sleep duration | No association |
| Van Reen et al. 2016 <br> [87] | $\begin{aligned} & \mathrm{C} \\ & (\mathrm{n}=878) \end{aligned}$ | 9 weeks | Alcohol | Daily use and heavy episodic drinking (diary) | Sleep diary | Sleep duration, sleep timing, sleep variability | Use vs non-use: later bedtime and rise time; no association with sleep duration |

## (a) Selected population ( $n=2$ )



| Goodhines, Gellis, Kim et al. 2019 | Alcohol and/ or cannabis consumers | 68 days | Alcohol, cannabis, OTC | Sleep aid use, frequency | ISI, MEQ, sleep diary | Sleep disturbance, sleep duration, sleep satisfaction, daytime | At baseline, sleep aid users: higher prevalence of sleep disturbances |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| [89] | (C) |  |  |  |  | dysfunction, chronotype | No longitudinal association |
|  | ( $\mathrm{n}=171$ ) |  |  |  |  |  |  |

## Notes

Abbreviations: C: College students only; G: College and non-college students recruited.
Questionnaires: CASQ: Cleveland Adolescent Sleepiness Questionnaire; CSM: Composite Scale of Morningness; ISI: Insomnia Severity Index; MEQ: Morningness-Eveningness
Questionnaire; PSQI: Pittsburgh Sleep Quality Index; STQ: Sleep Timing Questionnaire.
*Unpublished data from personal communication with authors.


[^0]:    Notes:
    Abbreviations: C: College students only; G: College and non-college students recruited (percentage in parenthesis represents number of college students in the sample, when reported;); nr: Not reported; F: Females.
    Questionnaires: AIS: Athens Insomnia Scale; ESS: Epworth Sleepiness Scale; ISI: Insomnia Severity Index; MOS-SS: Medical Outcome Study-Sleep Scale; PSQI: Pittsburgh Sleep Quality Index; PSSQ-I: Pittsburgh Sleep Symptoms Questionnaire- Insomnia; STQ: Sleep Timing Questionnaire
    *Unpublished data from personal communication with authors.

[^1]:    Notes:
    Abbreviations: C: College students only; G: College and non-college students recruited; nr: Not reported.
    Questionnaires: MEQ: Morningness-Eveningness Questionnaire; rMEQ: Morningness-Eveningness Questionnaire-reduced.
    *MEQ scores are reverse-coded: higher scores indicate a greater morning preference.

